<SEC-DOCUMENT>0001104659-25-084845.txt : 20250828
<SEC-HEADER>0001104659-25-084845.hdr.sgml : 20250828
<ACCEPTANCE-DATETIME>20250828171029
ACCESSION NUMBER:		0001104659-25-084845
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250827
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250828
DATE AS OF CHANGE:		20250828

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COGNITION THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001455365
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40886
		FILM NUMBER:		251274632

	BUSINESS ADDRESS:	
		STREET 1:		2403 SIDNEY STREET
		STREET 2:		SUITE 261
		CITY:			PITTSBURGH
		STATE:			PA
		ZIP:			15203
		BUSINESS PHONE:		412-481-2210

	MAIL ADDRESS:	
		STREET 1:		2500 WESTCHESTER AVE
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COGNITION THERAPUTICS INC
		DATE OF NAME CHANGE:	20090204
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2524576d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:cgtx="http://cogrx.com/20250827">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_cgtx_cogrx.com_20250827 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20250827_20250827 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0001455365 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-08-27" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-08-27" id="Fact000004" name="dei:EntityCentralIndexKey">0001455365</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cgtx-20250827.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-08-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001455365</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-27</xbrli:startDate>
        <xbrli:endDate>2025-08-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
</b></span><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_904_edei--DocumentType_c20250827__20250827_z4k6iZKIi2Uf"><ix:nonNumeric contextRef="AsOf2025-08-27" id="Fact000008" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT<br/>
Pursuant to Section&#160;13&#8239;OR  15(d)<br/>
of The Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported):&#160;<span id="xdx_90E_edei--DocumentPeriodEndDate_c20250827__20250827_z33Fq7g2DxXi"><ix:nonNumeric contextRef="AsOf2025-08-27" format="ixt:datemonthdayyearen" id="Fact000009" name="dei:DocumentPeriodEndDate">August 27, 2025</ix:nonNumeric></span></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span id="xdx_90F_edei--EntityRegistrantName_c20250827__20250827_zdycpzDl0txi"><ix:nonNumeric contextRef="AsOf2025-08-27" id="Fact000010" name="dei:EntityRegistrantName">Cognition
Therapeutics,&#160;Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span></span>
</b></span>(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20250827__20250827_zx7KcwNsljTh"><ix:nonNumeric contextRef="AsOf2025-08-27" format="ixt-sec:stateprovnameen" id="Fact000011" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityFileNumber_c20250827__20250827_zmtMCzKbYza2"><ix:nonNumeric contextRef="AsOf2025-08-27" id="Fact000012" name="dei:EntityFileNumber">001-40886</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20250827__20250827_zSVXUjSqwEkj"><ix:nonNumeric contextRef="AsOf2025-08-27" id="Fact000013" name="dei:EntityTaxIdentificationNumber">13-4365359</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of<br/>
incorporation)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(Commission <br/>
File Number)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 100%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20250827__20250827_zNkjwrbWbSq8"><ix:nonNumeric contextRef="AsOf2025-08-27" id="Fact000014" name="dei:EntityAddressAddressLine1">2500 Westchester Ave.</ix:nonNumeric></span><br/>
<span id="xdx_90B_edei--EntityAddressCityOrTown_c20250827__20250827_zYnuzlRrNTvh"><ix:nonNumeric contextRef="AsOf2025-08-27" id="Fact000015" name="dei:EntityAddressCityOrTown">Purchase</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20250827__20250827_zu0iNyYdxxZg"><ix:nonNumeric contextRef="AsOf2025-08-27" id="Fact000016" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span><br/>
</b></span><b>(<span id="xdx_900_edei--CityAreaCode_c20250827__20250827_zq57CdMGprk"><ix:nonNumeric contextRef="AsOf2025-08-27" id="Fact000017" name="dei:CityAreaCode">412</ix:nonNumeric></span>) <span id="xdx_90D_edei--LocalPhoneNumber_c20250827__20250827_zmv4CqDDFCfl"><ix:nonNumeric contextRef="AsOf2025-08-27" id="Fact000018" name="dei:LocalPhoneNumber">481-2210</ix:nonNumeric></span></b></td>
    </tr>
  <tr>
    <td style="vertical-align: top; text-align: center"/>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)&#160;</p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Not
Applicable<br/>
</b></span>(Former name or former address, if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form&#160;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.18in; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><span style="font-family: Wingdings"><span id="xdx_903_edei--WrittenCommunications_c20250827__20250827_zQFTsCkaJBRa"><ix:nonNumeric contextRef="AsOf2025-08-27" format="ixt:booleanfalse" id="Fact000019" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><p style="margin-top: 0; margin-bottom: 0"></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><span style="font-family: Wingdings"><span id="xdx_90F_edei--SolicitingMaterial_c20250827__20250827_zngN4Gs4SJ0k"><ix:nonNumeric contextRef="AsOf2025-08-27" format="ixt:booleanfalse" id="Fact000020" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><span style="font-family: Wingdings"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20250827__20250827_zDTQcVf1XgY9"><ix:nonNumeric contextRef="AsOf2025-08-27" format="ixt:booleanfalse" id="Fact000021" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&#160;</td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20250827__20250827_zh8daTJIQDeb"><ix:nonNumeric contextRef="AsOf2025-08-27" format="ixt:booleanfalse" id="Fact000022" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Securities registered
pursuant to Section&#160;12(b)&#160;of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 35%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title of each class</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 25%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 36%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--Security12bTitle_c20250827__20250827_zZerPqwV1oz2"><ix:nonNumeric contextRef="AsOf2025-08-27" id="Fact000023" name="dei:Security12bTitle">Common Stock, $0.001  par value&#8239;per share</ix:nonNumeric></span> </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--TradingSymbol_c20250827__20250827_zkXsJ6FOEnH"><ix:nonNumeric contextRef="AsOf2025-08-27" id="Fact000024" name="dei:TradingSymbol">CGTX</ix:nonNumeric></span></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--SecurityExchangeName_c20250827__20250827_zqwyM2DjYpm"><ix:nonNumeric contextRef="AsOf2025-08-27" format="ixt-sec:exchnameen" id="Fact000025" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2
of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company&#160;<span style="font-family: Wingdings"><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20250827__20250827_z6JhdMizor3l"><ix:nonNumeric contextRef="AsOf2025-08-27" format="ixt:booleantrue" id="Fact000026" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;<span style="font-family: Wingdings"><span id="xdx_90B_edei--EntityExTransitionPeriod_c20250827__20250827_z3nIfYKxXkC2"><ix:nonNumeric contextRef="AsOf2025-08-27" format="ixt:booleanfalse" id="Fact000027" name="dei:EntityExTransitionPeriod">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 10%"><b>Item 1.01.</b></td>
    <td style="font-size: 10pt; text-align: justify; width: 90%"><b>Entry into a Material Definitive Agreement.</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 27, 2025, Cognition Therapeutics, Inc.
(the &#8220;Company&#8221;) entered into Securities Purchase Agreements (the &#8220;Securities Purchase Agreements&#8221;) with two institutional
investors (the &#8220;Purchasers&#8221;) relating to the issuance of an aggregate of 14,700,000 shares of the Company&#8217;s common stock,
par value of $0.001 per share (the &#8220;Common Stock&#8221;) to such investors at a purchase price of $2.05 per share in a registered
direct offering (the &#8220;Offering&#8221;). The Company also entered into a Placement Agency Agreement on such date (the &#8220;Placement
Agency Agreement,&#8221; and together with the Securities Purchase Agreements, the &#8220;Agreements&#8221;) with Titan Partners Group
LLC, a division of American Capital Partners, LLC (&#8220;Titan&#8221;), who is acting as the sole placement agent for the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The gross proceeds from the Offering will be approximately
$30.1 million, before paying the placement agent fees and other estimated offering expenses. The Offering is being made pursuant to the
shelf registration statement on Form S-3 (File No. 333-268992) previously filed by the Company with the Securities and Exchange Commission
(the &#8220;SEC&#8221;) on December 23, 2022 and declared effective on January 3, 2023. The Offering is being made only by means of a
base prospectus forming a part of the effective registration statement and a prospectus supplement relating to the Offering. The Offering
is expected to close on or about August 29, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the Placement Agency Agreement,
the Company agreed to pay Titan an aggregate cash fee of 7.0% of the gross proceeds raised from the sale and issuance of the shares of
Common Stock minus certain expenses. Additionally, the Company agreed to issue warrants to Titan to purchase up to 514,500 shares of Common
Stock (the &#8220;Placement Agent Warrants&#8221;). The Placement Agent Warrants will have an exercise price equal to $2.78, and will
be exercisable commencing six months after the closing of the Offering with a term of five (5) years from the date of the Placement Agency
Agreement. Pursuant to the Placement Agency Agreement, the Company also agreed to reimburse Titan up to $100,000 for its expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Agreements contain customary representations,
warranties and covenants of the Company and also provide for customary indemnification obligations of the Company, including the liabilities
under the Securities Act of 1933, as amended. In connection with the Offering, the Company, pursuant to the Agreements, and each of the
Company&#8217;s directors and executive officers, pursuant to certain &#8220;lock-up&#8221; agreements, have agreed not to, without the
prior written consent of each of the Purchasers and Titan, sell, transfer or dispose securities of the Company for a period of 60 days
following the closing of the Offering, subject to customary exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Placement Agency Agreement, form of Placement
Agent Warrant and form of Securities Purchase Agreement are filed as Exhibit 1.1, 4.1 and 10.1, respectively, to this Current Report on
Form 8-K. The foregoing descriptions of the respective terms of the Agreements and the Placement Agent Warrants are not intended to be
complete and are qualified in their entirety by reference to each such exhibit. A copy of the opinion of Goodwin Procter LLP relating
to the legality of the issuance and sale of the securities in the Offering is filed as Exhibit 5.1 to this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 10%"><b>Item 9.01</b></td>
    <td style="font-size: 10pt; text-align: justify; width: 90%"><b>Financial Statements and Exhibits.</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d) Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt"><b>Exhibit<br/>
    No.</b></td>
    <td style="padding-top: 6pt"><b>Description</b></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt"><a href="tm2524576d2_ex1-1.htm" style="-sec-extract: exhibit">1.1*</a></td>
    <td style="padding-top: 6pt"><a href="tm2524576d2_ex1-1.htm" style="-sec-extract: exhibit">Placement Agency Agreement dated August 27, 2025.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt"><a href="tm2524576d2_ex4-1.htm" style="-sec-extract: exhibit">4.1*</a></td>
    <td style="padding-top: 6pt"><a href="tm2524576d2_ex4-1.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant. </a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt"><a href="tm2524576d2_ex5-1.htm" style="-sec-extract: exhibit">5.1*</a></td>
    <td style="padding-top: 6pt"><a href="tm2524576d2_ex5-1.htm" style="-sec-extract: exhibit">Opinion of Goodwin Procter LLP.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt"><a href="tm2524576d2_ex10-1.htm" style="-sec-extract: exhibit">10.1*</a></td>
    <td style="padding-top: 6pt"><a href="tm2524576d2_ex10-1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement dated August 27, 2025.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt"><a href="tm2524576d2_ex5-1.htm" style="-sec-extract: exhibit">23.1*</a></td>
    <td style="padding-top: 6pt"><a href="tm2524576d2_ex5-1.htm" style="-sec-extract: exhibit">Consent of Goodwin Procter LLP (included in Exhibit 5.1).</a></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt">104</td>
    <td style="padding-top: 6pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Exchange Act,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COGNITION THERAPEUTICS,&#160;INC.</b></span></td></tr>
  <tr>
    <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August&#160;28, 2025</span></td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Lisa Ricciardi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lisa Ricciardi</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2524576d2_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Execution Version</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLACEMENT AGENCY AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">August&nbsp;27, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Titan Partners Group LLC,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a division of American Capital Partners, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4 World Trade Center, 29th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10007</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Introductory</B>. This
Placement Agency Agreement (this &ldquo;<B>Agreement</B>&rdquo;) sets forth the terms upon which Titan Partners Group LLC, a division
of American Capital Partners, LLC (&ldquo;<B>Titan Partners</B>&rdquo; or the &ldquo;<B>Placement Agent</B>&rdquo;), shall be engaged
by Cognition Therapeutics,&nbsp;Inc., a company incorporated under the laws of Delaware (the &ldquo;<B>Company</B>&rdquo;), to act as
the exclusive Placement Agent in connection with the registered direct offering (hereinafter referred to as the &ldquo;<B>Placement</B>&rdquo;)
of (i)&nbsp;shares of common stock, par value $0.001 per share (the &ldquo;<B>Common Stock</B>&rdquo; and the Common Stock offered in
the Placement, the &ldquo;<B>Placement Common Stock</B>&rdquo;), of the Company, and (ii)&nbsp;pre-funded warrants (the &ldquo;<B>Pre-funded
Warrants</B>&rdquo;) to purchase shares of Common Stock at an exercise price equal to $0.001 per share. The Placement Common Stock and
the Pre-funded Warrants are collectively referred to as the &ldquo;<B>Placement Securities</B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the Placement
and the Placement Securities shall be mutually agreed upon by the Company and the purchasers (each, a &ldquo;<B>Purchaser</B>&rdquo; and
collectively, the &ldquo;<B>Purchasers</B>&rdquo;) and nothing herein constitutes that the Placement Agent would have the power or authority
to bind the Company or any Purchaser or an obligation for the Company to issue any Placement Securities or complete the Placement. The
date of the closing of the Placement shall be referred to herein as the &ldquo;<B>Closing Date</B>&rdquo;. The Company expressly acknowledges
and agrees that the Placement Agent&rsquo;s obligations hereunder are on a reasonable best efforts basis only and that the execution of
this Agreement does not constitute a commitment by the Placement Agent to purchase the Placement Securities and does not ensure the successful
placement of the Placement Securities or any portion thereof or the success of the Placement Agent with respect to securing any other
financing on behalf of the Company. Following the prior written consent of the Company, the Placement Agent may retain other brokers or
dealers to act as sub-agents or selected-dealers on its behalf in connection with the Placement. The sale of the Placement Securities
to any Purchaser will be evidenced by a securities purchase agreement (the &ldquo;<B>Purchase Agreement</B>&rdquo;) by and among the Company
and such Purchasers in the form of <U>Exhibit&nbsp;A</U> attached hereto. Capitalized terms that are not otherwise defined herein have
the meanings given to such terms in the Purchase Agreement. Prior to the signing of any Purchase Agreement, executive officers of the
Company will be available upon reasonable notice and during normal business hours to answer inquiries from prospective Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION&nbsp;1</U>. <U>REPRESENTATIONS
AND WARRANTIES OF THE COMPANY; COVENANTS OF THE COMPANY</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A. <U>Representations of the
Company</U>. With respect to the Placement Securities, each of the representations and warranties (together with any related disclosure
schedules thereto) and covenants made by the Company to the Purchasers in the Purchase Agreement in connection with the Placement, is
hereby incorporated herein by reference into this Agreement (as though fully restated herein) and is, as of the date of this Agreement
and as of the Closing Date, hereby made to, and in favor of, the Placement Agent. In addition to the foregoing, the Company represents
and warrants that there are no affiliations with any FINRA member firm participating in the Placement among the Company&rsquo;s officers,
directors or, to the knowledge of the Company, any ten percent (10%) or greater stockholder of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. <U>Covenants of the Company</U>.
The Company covenants and agrees to continue to retain (i)&nbsp;a firm of independent PCAOB registered public accountants for a period
of at least five (5)&nbsp;years after the Closing Date and (ii)&nbsp;a transfer agent with respect to the Common Stock for a period of
five (5)&nbsp;years after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION&nbsp;2</U>. <U>REPRESENTATIONS
OF THE PLACEMENT AGENT</U>. The Placement Agent represents and warrants that it (i)&nbsp;is a member in good standing of the Financial
Industry Regulatory Authority (&ldquo;<B>FINRA</B>&rdquo;), (ii)&nbsp;is registered as a broker/dealer under the Securities Exchange Act
of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), (iii)&nbsp;is licensed as a broker/dealer under the laws of the United States
of America, applicable to the offers and sales of the Placement Securities by the Placement Agent, (iv)&nbsp;is and will be a corporate
body validly existing under the laws of its place of incorporation, and (v)&nbsp;has full power and authority to enter into and perform
its obligations under this Agreement. The Placement Agent will immediately notify the Company in writing of any change in its status with
respect to subsections (i)&nbsp;through (v)&nbsp;above. The Placement Agent covenants that it will use its reasonable best efforts to
conduct the Placement hereunder in compliance with the provisions of this Agreement and the requirements of applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION&nbsp;3</U>. <U>COMPENSATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A. <U>Cash Compensation</U>.
In consideration of the services to be provided for hereunder, the Company shall pay to the Placement Agent or its respective designees
a total cash fee equal to seven percent (7%) of the gross proceeds from the Placement of the total amount of Placement Securities sold,
minus $175,000 (collectively, the &ldquo;<B>Cash Fee</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. <U>Warrant Compensation</U>.
In consideration of the services to be provided for hereunder, the Company shall pay to the Placement Agent or its respective designees
at the Closing Date, warrants (&ldquo;<B>Agent Warrants</B>&rdquo;) for the purchase of an aggregate of a number of shares of Common Stock
(the &ldquo;<B>Agent Warrant Shares</B>&rdquo;), representing three and a half percent (3.5%) of the Placement Securities sold at the
Closing Date. The Agent Warrants, in the form of Exhibit&nbsp;C hereto, shall be exercisable, in whole or in part, &nbsp;commencing on
the date that is 6 months after the Closing Date&nbsp;and expiring on the five-year anniversary of the date of this Agreement at an initial
exercise price per share of Common Stock of $2.78. The Placement Agent understands and agrees that there are significant restrictions
pursuant to FINRA Rule&nbsp;5110 against transferring the Agent Warrants and the Agent Warrant Shares during the one hundred eighty (180)
days after this Agreement and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the
Agent Warrants, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call transaction that would result
in the effective economic disposition of such securities for a period of one hundred eighty (180) days following the date of this Agreement
to anyone other than (i)&nbsp;a sub-agent or selected-dealer in connection with the Placement or (ii)&nbsp;a bona fide officer, partner,
employee or registered representative of the Placement Agent, sub-agent or selected-dealer; and only if any such transferee agrees to
the foregoing lock-up restrictions. Delivery of the Agent Warrants shall be made at the relevant Closing Date, and shall be issued in
the name or names and in such authorized denominations as the Placement Agent may request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C. <U>Reduction of Compensation</U>.
The Placement Agent reserves the right to reduce any item of compensation or adjust the terms thereof as specified herein in the event
that a determination shall be made by FINRA to the effect that the Placement Agent&rsquo;s aggregate compensation is in excess of FINRA
Rules&nbsp;or that the terms thereof require adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION&nbsp;4. EXPENSES</U>.
The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in
connection with the transactions contemplated hereby, including, without limitation: (i)&nbsp;all expenses incident to the issuance, delivery
and qualification of the Placement Securities (including all printing and engraving costs); (ii)&nbsp;all fees and expenses of the registrar
and transfer agent for the Common Stock ; (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the issuance
and sale of the Placement Securities; (iv)&nbsp;all fees and expenses of the Company&rsquo;s counsel, independent public or certified
public accountants and other advisors; (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing,
shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates
of experts), and the Prospectus, and all amendments and supplements thereto, and this Agreement; (vi)&nbsp;all filing fees, reasonable
attorneys&rsquo; fees and expenses incurred by the Company in connection with qualifying or registering (or obtaining exemptions from
the qualification or registration of) all or any part of the Placement Securities for offer and sale under the state securities or blue
sky laws or the securities laws of any other country; (vii)&nbsp;the fees and expenses associated with including the Placement Common
Stock on the Trading Market; (viii)&nbsp;up to $100,000 for the fees and expenses of the Placement Agent, including the fees and expenses
of McGuireWoods LLP, counsel to the Placement Agent. The Placement Agent may deduct from the net proceeds of the Offering payable to the
Company on the Closing Date, the expenses set forth herein to be paid by the Company to the Placement Agent, to the extent not already
paid. If the Placement is not consummated, the Company shall reimburse the Placement Agent for reasonable out-of-pocket expenses incurred
by Titan Partners in connection with the Placement, up to $50,000, including the actual fees and disbursements of its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION&nbsp;5</U>. <U>INDEMNIFICATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A. To the extent permitted by
law, with respect to the Placement Securities, the Company will indemnify the Placement Agent and its affiliates, stockholders, directors,
officers, employees, members and controlling persons (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of
the Exchange Act) against all losses, claims, damages, expenses and liabilities, as the same are incurred (including the reasonable fees
and expenses of counsel), relating to or arising out of its activities hereunder or pursuant to this Agreement or the Purchase Agreement,
including, without limitation, any failure by the Company to obtain any required consent, except to the extent that any losses, claims,
damages, expenses or liabilities (or actions in respect thereof) are found in a final judgment (not subject to appeal) by a court of law
to have resulted primarily and directly from a Placement Agent&rsquo;s willful misconduct or gross negligence in performing the services
described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. Promptly after receipt by
the Placement Agent of notice of any claim or the commencement of any action or proceeding with respect to which the Placement Agent is
entitled to indemnity hereunder, the Placement Agent will promptly notify the Company in writing of such claim or of the commencement
of such action or proceeding, but failure to so notify the Company shall not relieve the Company from any obligation it may have hereunder,
except and only to the extent such failure results in the forfeiture by the Company of substantial rights and defenses. If the Company
so elects or is requested by the Placement Agent, the Company will assume the defense of such action or proceeding and will employ counsel
reasonably satisfactory to the Placement Agent and will pay the fees and expenses of such counsel. Notwithstanding the preceding sentence,
the Placement Agent will be entitled to employ its own counsel separate from counsel for the Company and from any other party in such
action if counsel for the Placement Agent reasonably determines that it would be inappropriate under the applicable rules&nbsp;of professional
responsibility for the same counsel to represent both the Company and the Placement Agent. In such event, the reasonable fees and disbursements
of no more than one such separate counsel will be paid by the Company, in addition to fees of local counsel. The Company will have the
right to settle the claim or proceeding, provided that the Company will not settle any such claim, action or proceeding without the prior
written consent of the Placement Agent, which will not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C. The Company agrees to notify
the Placement Agent promptly of the assertion against it or any other person of any claim or the commencement of any action or proceeding
relating to a transaction contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">D. If for any reason the foregoing
indemnity is unavailable to the Placement Agent or insufficient to hold the Placement Agent harmless, then the Company shall contribute
to the amount paid or payable by the Placement Agent as a result of such losses, claims, damages or liabilities in such proportion as
is appropriate to reflect not only the relative benefits received by the Company on the one hand and the Placement Agent on the other,
but also the relative fault of the Company on the one hand and the Placement Agent on the other that resulted in such losses, claims,
damages or liabilities, as well as any relevant equitable considerations. The amounts paid or payable by a party in respect of losses,
claims, damages and liabilities referred to above shall be deemed to include any legal or other fees and expenses incurred in defending
any litigation, proceeding or other action or claim. Notwithstanding the provisions hereof, the Placement Agent&rsquo;s share of the liability
hereunder shall not be in excess of the amount of fees actually received, or to be received, by the Placement Agent under this Agreement
(excluding any amounts received as reimbursement of expenses incurred by the Placement Agent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E. These indemnification provisions
shall remain in full force and effect whether or not the transaction contemplated by this Agreement is completed and shall survive the
termination of this Agreement, and shall be in addition to any liability that the Company might otherwise have to any indemnified party
under this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION&nbsp;6</U>. <U>ENGAGEMENT
TERM</U>. The Placement Agent&rsquo;s engagement hereunder will be until the later of (i)&nbsp;September&nbsp;3, 2025 and (ii)&nbsp;the
final Closing Date under the Purchase Agreement. The date of termination of this Agreement is referred to herein as the &ldquo;<B>Termination
Date</B>.&rdquo; In the event, however, in the course of the Placement Agent&rsquo;s performance of due diligence it deems it necessary
to terminate the engagement, the Placement Agent may do so prior to the Termination Date. The Company may elect to terminate the engagement
hereunder for any reason prior to the Termination Date but will remain responsible for fees pursuant to Section&nbsp;3 hereof with respect
to the Placement Securities if sold in the Placement. Notwithstanding anything to the contrary contained herein, the provisions concerning
the Company&rsquo;s obligation to pay any fees actually earned pursuant to Section&nbsp;3 hereof and the provisions concerning confidentiality,
indemnification and contribution contained herein will survive any expiration or termination of this Agreement. If this Agreement is terminated
prior to the completion of the Placement, all fees due to the Placement Agent as set forth in Section&nbsp;3 shall be paid by the Company
to the Placement Agent on or before the Termination Date (in the event such fees are earned or owed as of the Termination Date). The Placement
Agent agrees not to use any confidential information concerning the Company provided to the Placement Agent by the Company for any purposes
other than those contemplated under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION&nbsp;7</U>. <U>PLACEMENT
AGENT INFORMATION</U>. The Company agrees that any information or advice rendered by the Placement Agent in connection with this engagement
is for the confidential use of the Company only in its evaluation of the Placement and, except as otherwise required by law, the Company
will not disclose or otherwise refer to the advice or information in any manner without the Placement Agent&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION&nbsp;8</U>. <U>NO
FIDUCIARY RELATIONSHIP</U>. This Agreement does not create, and shall not be construed as creating rights enforceable by any person or
entity not a party hereto, except those entitled hereto by virtue of the indemnification provisions hereof. The Company acknowledges and
agrees that the Placement Agent is not and shall not be construed as a fiduciary of the Company and shall have no duties or liabilities
to the equity holders or the creditors of the Company or any other person by virtue of this Agreement or the retention of the Placement
Agent hereunder, all of which are hereby expressly waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION&nbsp;9</U>. <U>CLOSING</U>.
The obligations of the Placement Agent, and the closing of the sale of the Placement Securities hereunder are subject to the accuracy,
when made and on the Closing Date, of the representations and warranties on the part of the Company contained herein and in the Purchase
Agreement, to the performance by the Company of its obligations hereunder, and to each of the following additional terms and conditions,
except as otherwise disclosed to and acknowledged and waived by the Placement Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A. All corporate proceedings
and other legal matters incident to the authorization, form, execution, delivery and validity of each of this Agreement, the Placement
Securities, and all other legal matters relating to this Agreement and the transactions contemplated hereby with respect to the Placement
Securities shall be reasonably satisfactory in all material respects to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. The Placement Agent shall
have received the following on the Closing Date: (i)&nbsp;the favorable opinion and written statement providing certain &ldquo;10b-5&rdquo;
negative assurances of Goodwin Procter LLP, counsel to the Company, dated as of the Closing Date and addressed to the Placement Agent,
in form and substance reasonably satisfactory to the Placement Agent and (ii)&nbsp;the favorable opinion and a written statement provided
certain &ldquo;10b-5&rdquo; negative assurances of <FONT STYLE="background-color: white">intellectual property legal counsel to the Company</FONT>,
dated as of the Closing Date and addressed to the Placement Agent, in form and substance reasonably satisfactory to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C. The Placement Agent shall
have received (i)&nbsp;on the Closing Date, a customary Officers&rsquo; Certificate, executed and delivered by the Company&rsquo;s executive
officers, as to the accuracy of the representations and warranties contained in the Purchase Agreement, (ii)&nbsp;on the date hereof,
a Chief Financial Officer&rsquo;s Certificate regarding certain financial information included in the Registration Statement and Prospectus
in form and substance reasonably satisfactory in all respects to the Placement Agent, (iii)&nbsp;on the Closing Date, a cold comfort letter
from the Auditor addressed to the Board of Directors and the Placement Agent, in form and substance reasonably satisfactory in all respects
to the Placement Agent; and (iv)&nbsp;on the Closing Date, a Secretary&rsquo;s Certificate executed and delivered by the Company&rsquo;s
corporate secretary certifying that (A)&nbsp;the Company&rsquo;s charter documents are true and complete, have not been modified and are
in full force and effect; (B)&nbsp;that the resolutions of the Company&rsquo;s Board of Directors relating to the Placement are in full
force and effect and have not been modified; (C)&nbsp;as to the incumbency of the officers of the Company and (D)&nbsp;other customary
certifications reasonably satisfactory to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E. The Placement Agent shall
have received an executed FINRA questionnaire from each of the Company and the Company&rsquo;s executive officers, directors and 10% or
greater securityholders, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">F. The Placement Agent shall
have received, on or before the date of this Agreement, executed copies of the Lock-Up Agreement, the form of which is attached hereto
as Exhibit&nbsp;B, from each of the persons listed on Schedule A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">G. The Placement Agent shall
have received on the Closing Date satisfactory evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions
of organization and their good standing as foreign corporations in such other jurisdictions as the Placement Agent may reasonably request,
in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions,
dated no more than one (1)&nbsp;business day prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">H. The Placement Common Stock
shall be registered under the Exchange Act. The Company shall have taken no action designed to, or likely to have the effect of terminating
the registration of the Common Stock under the Exchange Act or delisting or suspending from trading the Common Stock from the Trading
Market or other applicable U.S. national exchange, nor has the Company received any information suggesting that the Commission or the
Trading Market or other U.S. applicable national exchange is contemplating terminating such registration or listing. In addition, the
Company shall have submitted a listing of additional shares notification form to the Nasdaq Stock Market, LLC (&ldquo;<B>Nasdaq</B>&rdquo;)
with respect to the Placement Shares and shall have received no objection thereto from Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">I. No action shall have been
taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental agency or body which would,
as of the Closing Date, prevent the issuance or sale of the Placement Securities or materially and adversely affect or potentially and
adversely affect the business or operations of the Company; and no injunction, restraining order or order of any other nature by any federal
or state court of competent jurisdiction shall have been issued as of the Closing Date which would prevent the issuance or sale of the
Placement Securities or materially and adversely affect or potentially and adversely affect the business or operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">J. The Company shall have entered
into a Purchase Agreement with each of the Purchasers of the Placement Securities and such agreements shall be in full force and effect
and shall contain representations, warranties and covenants of the Company as agreed upon between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">K. FINRA shall have raised no
objection to the fairness and reasonableness of the terms and arrangements of this Agreement. In addition, the Company shall, if requested
by the Placement Agent, make or authorize Placement Agent&rsquo;s counsel to make on the Company&rsquo;s behalf, any filing with the FINRA
Corporate Financing Department pursuant to FINRA Rule&nbsp;5110 with respect to the Placement and pay all filing fees required in connection
therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the conditions specified
in this Section&nbsp;9 shall not have been fulfilled when and as required by this Agreement, all obligations of the Placement Agent hereunder
may be cancelled by the Placement Agent at, or at any time prior to, any Closing Date. Notice of such cancellation shall be given to the
Company in writing or orally. Any such oral notice shall be confirmed promptly thereafter in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION&nbsp;10</U>. <U>GOVERNING
LAW</U>. This Agreement will be governed by, and construed in accordance with, the laws of the State of New York applicable to agreements
made and to be performed entirely in such State, without regard to principles of conflicts of law. This Agreement may not be assigned
by either party without the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit of
the parties hereto, and their respective successors and permitted assigns. Any right to trial by jury with respect to any dispute arising
under this Agreement or any transaction or conduct in connection herewith is waived. Any dispute arising under this Agreement may be brought
into the courts of the State of New York or into the Federal Court located in New York, New York and, by execution and delivery of this
Agreement, the Company hereby accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of aforesaid
courts. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by delivering a copy thereof via overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If either
party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or
proceeding shall be reimbursed by the other party for its attorney's fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION&nbsp;11</U>. <U>ENTIRE
AGREEMENT/MISCELLANEOUS</U>. This Agreement embodies the entire agreement and understanding between the parties hereto, and supersedes
all prior agreements and understandings, relating to the subject matter hereof. If any provision of this Agreement is determined to be
invalid or unenforceable in any respect, such determination will not affect such provision in any other respect or any other provision
of this Agreement, which will remain in full force and effect. This Agreement may not be amended or otherwise modified or waived except
by an instrument in writing signed by both the Placement Agent and the Company. The representations, warranties, agreements and covenants
contained herein shall survive the Closing Date of the Placement and delivery of the Placement Securities. This Agreement may be executed
in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective
when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign
the same counterpart. In the event that any signature is delivered by facsimile transmission or a .pdf format file, such signature shall
create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile or .pdf signature page&nbsp;were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION&nbsp;12</U>.<I>&nbsp;</I><U>NOTICES</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a)&nbsp;the date of transmission, if such notice or communication is sent to the email
address specified on the signature pages&nbsp;attached hereto prior to 6:30 p.m.&nbsp;(New York City time) on a business day, (b)&nbsp;the
next business day after the date of transmission, if such notice or communication is sent to the email address on the signature pages&nbsp;attached
hereto on a day that is not a business day or later than 6:30 p.m.&nbsp;(New York City time) on any business day, (c)&nbsp;the third business
day following the date of mailing, if sent by U.S. internationally recognized air courier service, or (d)&nbsp;upon actual receipt by
the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature
pages&nbsp;hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>SECTION&nbsp;13</U>. <U>PRESS
ANNOUNCEMENTS</U>. The Company agrees that the Placement Agent shall, on and after the Closing Date, have the right to reference the Placement
and the Placement Agent&rsquo;s role in connection therewith in the Placement Agent&rsquo;s marketing materials and on its website and
to place advertisements in financial and other newspapers and journals, in each case at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>SECTION&nbsp;14</U>. <U>STANDSTILL</U>. Without
the prior written consent of the Placement Agent, from the date hereof until sixty (60) days after the Closing Date, neither the Company
nor any subsidiary shall (i)&nbsp;issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Common
Stock or common stock equivalents, other than an Exempt Issuance or (ii)&nbsp;file any registration statement or any amendment or supplement
thereto. For purposes of this Agreement, &ldquo;<B>Exempt Issuance</B>&rdquo; means the issuance of (a)&nbsp;shares of Common Stock or
options to employees, officers or directors of the Company pursuant to any share or option plan duly adopted for such purpose, by a majority
of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established
for such purpose for services rendered to the Company, (b)&nbsp;securities upon the exercise or exchange of or conversion of securities
exercisable or exchangeable for or convertible into Common Stock issued and outstanding on the date of this Agreement, provided that such
securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise
price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend
the term of such securities, (c)&nbsp;the securities of the Company issued pursuant to the Purchase Agreements and (d)&nbsp;securities
issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided
that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule&nbsp;144) and carry no registration rights
that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section&nbsp;14
herein and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through
its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide
to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is
issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature page&nbsp;follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please confirm that the foregoing
correctly sets forth our agreement by signing and returning to the Placement Agents the enclosed copy of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TITAN PARTNERS GROUP LLC,</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>A DIVISION OF AMERICAN CAPITAL PARTNERS, LLC</B></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Adam Sands</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Adam Sands</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Authorized Representative</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address for notice:</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Titan Partners Group LLC, a division of American Capital Partners,
    LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4 World Trade Center, 29th Floor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10007</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Adam Sands</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: notices@titanpartnersgrp.com</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted and Agreed to as of the date first written above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COGNITION THERAPEUTICS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ Lisa Ricciardi</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Lisa Ricciardi</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Address for notice</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cognition Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2500 Westchester Ave.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Purchase, NY 10577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Lisa Ricciardi</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: lricciardi@cogrx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>List of Lock-up Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Form&nbsp;of
Securities Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM&nbsp;OF LOCK-UP AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Form&nbsp;of
AGENT&rsquo;S PURCHASE WARRANT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>tm2524576d2_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AGENT&rsquo;S PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>COGNITION
THERAPEUTICS,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 48%; text-align: left">Warrant Shares: _________<SUP>1</SUP></TD>
    <TD STYLE="width: 2%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 40%; font: bold 10pt Times New Roman, Times, Serif; text-align: right">Initial
Exercise Date: [__], 2026</TD><TD STYLE="width: 10%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><SUP>2</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><B>Issue Date: [__], 2025</B></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This <B>AGENT&rsquo;S PURCHASE
WARRANT</B> (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, American Capital Partners, LLC or its assigns (the
&ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
forth, at any time on or after the date referred to above as the Initial Exercise Date (the &ldquo;<U>Initial Exercise Date</U>&rdquo;)
and on or prior to 5:00 p.m.&nbsp;(New York City time) on [__], 2030<SUP>3</SUP> (the &ldquo;<U>Termination Date</U>&rdquo;) but not
thereafter, to subscribe for and purchase from Cognition Therapeutics,&nbsp;Inc., a company incorporated under the laws of Delaware (the
&ldquo;<U>Company</U>&rdquo;), up to _______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common
Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Placement Agency Agreement (the
&ldquo;<U>Placement Agreement</U>&rdquo;), dated August&nbsp;27, 2025, between the Company and Titan Partners Group LLC, a division of
American Capital Partners, LLC, as placement agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;2</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy
or PDF copy submitted by email (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i)&nbsp;one (1)&nbsp;Trading Day and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period
(as defined in Section&nbsp;2(d)(i)&nbsp;herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise
Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United
States bank unless the cashless exercise procedure specified in Section&nbsp;2(c)&nbsp;below is specified in the applicable Notice of
Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1)&nbsp;Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of
this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on
the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
Insert 3.5% of the total shares and pre-funded warrants, if any, sold in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT>
Insert the date that is 6 months after the date of the closing of the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3</SUP></FONT>
Insert the 5-year anniversary date of the Placement Agent Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $____<SUP>4</SUP>, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Cashless
Exercise</U>. In lieu of exercising this Warrant by delivering the aggregate Exercise Price by wire transfer or cashier&rsquo;s check,
at the election of Holder, if at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(A)&nbsp;= as applicable:
(i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is
(1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a day that is not a Trading Day or (2)&nbsp;both executed
and delivered pursuant to Section&nbsp;2(a)&nbsp;hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as
defined in Rule&nbsp;600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the
option of the Holder, either (y)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section&nbsp;2(a)&nbsp;hereof or (iii)&nbsp;the VWAP on the date of the applicable
Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered
pursuant to Section&nbsp;2(a)&nbsp;hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B)&nbsp;= the
Exercise Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">(X)&nbsp;= the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&ldquo;<U>VWAP</U>&rdquo; means, for
any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock are then listed or quoted
on The New York Stock Exchange, the NYSE American or any tier of The Nasdaq Stock Market (each, a &ldquo;<U>Trading Market</U>&rdquo;),
the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which
the Common Stock are then listed or quoted as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) (based on a trading day from
9:30 a.m.&nbsp;(New York City time) to 4:02 p.m.&nbsp;(New York City time)), (b)&nbsp; if the Common Stock are listed or quoted on the
OTCQB or OTCQX (each as operated by OTC Markets Group,&nbsp;Inc., or any successor market), the volume weighted average price of the Common
Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock are not then listed
or quoted for trading on the OTCQB or OTCQX Markets and if prices for the Common Stock are then reported in the OTC Pink Market published
by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price
per share of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a Common Stock as determined by an
independent appraiser selected in good faith by the Board of Directors of the Company and reasonably acceptable to the Holder, the fees
and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>4</SUP></FONT>
Insert an exercise price equal to 125% of the public offering price of the shares (but in no event lower than the Nasdaq &ldquo;Minimum
Price&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section&nbsp;3(a)(9)&nbsp;of the Securities
Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised, and the holding period of the Warrants
being exercised may be tacked onto the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this
Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">i.</FONT> <FONT STYLE="font-size: 10pt"><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B)&nbsp;this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i)&nbsp;one (1)&nbsp;Trading Day after the delivery to the Company by the Holder of the Notice of Exercise, (ii)&nbsp;one (1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to the Company and (iii)&nbsp;the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;)</FONT>; <FONT STYLE="font-size: 10pt"><U>provided</U>, <U>however</U>, that if payment of the aggregate Exercise Price is received after 12:00 P.M., New York City time on the Warrant Share Delivery Date, then the Warrant Share Delivery Date shall be extended by one (1)&nbsp;additional Trading Day. Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, <U>provided</U> that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i)&nbsp;one (1)&nbsp;Trading Day and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $5 per Trading Day (increasing to $10 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)&nbsp;by
the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise; <U>provided, however</U>, that the Holder
shall be required to return any Warrant Shares or Common Stock subject to any such rescinded exercise notice concurrently with the return
to the Holder of the aggregate Exercise Price paid to the Company for such Warrant Shares and the restoration of the Holder&rsquo;s right
to acquire such Warrant Shares pursuant to this Warrant (including, issuance of a replacement warrant certificate evidencing such restored
right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i)&nbsp;above
pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&rsquo;s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying
(1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence
the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form&nbsp;attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all
Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;Attribution Parties&rdquo;)), would
beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial
ownership shall be calculated in accordance with Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section&nbsp;13(d)&nbsp;of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section&nbsp;2(e)&nbsp;applies, the determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the
Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement
by the Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common
Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants,
9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable
upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions
of this Section&nbsp;2(e), <U>provided</U> that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares
of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held
by the Holder and the provisions of this Section&nbsp;2(e)&nbsp;shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e)&nbsp;to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;3</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification of
shares of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a)&nbsp;shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification. For the purposes of clarification, the Exercise
Price of this Warrant will not be adjusted in the event that the Company or any subsidiary thereof, as applicable, sells or grants any
option to purchase, or sell or any grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or
any option to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less than the
Exercise Price then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a)&nbsp;above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, to the extent that the
Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the
Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Pro
Rata Distribution</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution (other than cash) of stock or other securities, property or options by way of a dividend, spin off,
reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the
time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has
exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Fundamental
Transaction.</U> If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company (and all of its Subsidiaries,
taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of
all or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer,
tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50%
of the outstanding Common Stock, (iv)&nbsp;the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires greater than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or
other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase
agreement or other business combination) (each a &ldquo;Fundamental Transaction&rdquo;), then, upon any subsequent exercise of this Warrant,
the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior
to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section&nbsp;2(e)&nbsp;on
the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it
is the surviving corporation, and any additional consideration (the &ldquo;Alternate Consideration&rdquo;) receivable as a result of such
Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to
such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company
shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;Successor Entity&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the
provisions of this Section&nbsp;3(e)&nbsp;pursuant to written agreements in form and substance reasonably satisfactory to the Holder and
approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver
to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar
in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity
(or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard
to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the
exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant
to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Calculations</U>.
All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section&nbsp;3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notice
to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (and all of its Subsidiaries, taken as
a whole) is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile
or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least
20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a
record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken,
the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected
to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to
exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger,
sale, transfer or share exchange; <U>provided</U> that the failure to deliver such notice or any defect therein or in the delivery thereof
shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided
in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form&nbsp;8-K. The Holder shall remain entitled
to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice
except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;4</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Transferability</U>.
Pursuant to FINRA Rule&nbsp;5110(e)(1), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold,
transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that
would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the
commencement of sales of the offering pursuant to which this Warrant is being issued, except as permitted under FINRA Rule&nbsp;5110(e)(2).
Subject to the foregoing restriction, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this
Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially
in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable
upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant
or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant
to the Company within three (3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form to the Company assigning
this Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of
Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by or on behalf of the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Representation
by Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section&nbsp;6</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly
set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section&nbsp;2(c)&nbsp;or to receive cash payments pursuant to Section&nbsp;2(d)(i)&nbsp;and Section&nbsp;2(d)(iv)&nbsp;herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Saturdays,
Sundays, Holidays,&nbsp;etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the
duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such
reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that
all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the
purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued,
fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other
than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Governing
Law; Venue</U>. This Warrant shall be deemed to have been executed and delivered in New York and both this Warrant and the transactions
contemplated hereby shall be governed as to validity, interpretation, construction, effect, and in all other respects by the laws of the
State of New York applicable to agreements wholly performed within the borders of such state and without regard to the conflicts of laws
principals thereof (other than Section&nbsp;5-1401 of The New York General Obligations Law). Each of the Holder and the Company: (a)&nbsp;agrees
that any legal suit, action or proceeding arising out of or relating to this Warrant and/or the transactions contemplated hereby shall
be instituted exclusively in the Supreme Court of the State of New York, New York County, or in the United States District Court for the
Southern District of New York, (b)&nbsp;waives any objection which it may have or hereafter to the venue of any such suit, action or proceeding,
and (c)&nbsp;irrevocably consents to the jurisdiction of Supreme Court of the State of New York, New York County, or in the United States
District Court for the Southern District of New York in any such suit, action or proceeding. Each of the Holder and the Company further
agrees to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding in the Supreme
Court of the State of New York, New York County, or in the United States District Court for the Southern District of New York and agrees
that service of process upon the Company mailed by certified mail to the Company&rsquo;s address or delivered by Federal Express via overnight
delivery shall be deemed in every respect effective service of process upon the Company, in any such suit, action or proceeding, and service
of process upon the Holder mailed by certified mail to the Holder&rsquo;s address or delivered by Federal Express via overnight delivery
shall be deemed in every respect effective service process upon the Holder, in any such suit, action or proceeding. THE HOLDER (ON BEHALF
OF ITSELF,&nbsp;ITS SUBSIDIARIES AND, TO THE FULLEST EXTENT PERMITTED BY LAW, ON BEHALF OF ITS RESPECTIVE EQUITY HOLDERS AND CREDITORS)
HEREBY WAIVES ANY RIGHT HOLDER MAY&nbsp;HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION WITH
THIS WARRANT AND THE TRANSACTIONS CONTEMPLATED BY THIS WARRANT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
Any and all notices or other communications or deliveries to be provided hereunder shall be made in accordance with Section&nbsp;12 of
the Placement Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder of this Warrant, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page&nbsp;Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>COGNITION THERAPEUTICS,&nbsp;INC.</B> &nbsp; &nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: &nbsp;</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>COGNITION
THERAPEUTICS,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">  <FONT STYLE="font-family: Wingdings">&#168;</FONT>&#8239;&#8239;in lawful money of the United States;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">  <FONT STYLE="font-family: Wingdings">&#168;</FONT>&#8239;&#8239;if permitted the cancellation of
such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with
respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Investing Entity: ___________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Signature of Authorized Signatory of Investing Entity</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Authorized Signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title of Authorized Signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; width: 50%; font-size: 10pt; text-align: justify; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; width: 50%; font-size: 10pt; text-align: justify; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; font-size: 10pt; text-align: justify; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 2pt; font-size: 10pt; text-align: justify; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; font-size: 10pt; text-align: justify; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone Number:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address: </P></TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please
                                            Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 18pt">____________________________________</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; font-size: 10pt; text-align: justify; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________, ______</FONT></TD>
    <TD STYLE="padding-top: 2pt; font-size: 10pt; text-align: justify; padding-bottom: 2pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; font-size: 10pt; text-align: justify; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:_______________________________________<U></U></FONT></TD>
    <TD STYLE="padding-top: 2pt; font-size: 10pt; text-align: justify; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; font-size: 10pt; text-align: justify; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Address:________________________________________<U></U></FONT></TD>
    <TD STYLE="padding-top: 2pt; font-size: 10pt; text-align: justify; padding-bottom: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>tm2524576d2_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 49%; padding-right: 2pt; padding-left: 3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="tm2524576d2_ex5-1img001.jpg" ALT="A pair of black rings&#10;&#10;AI-generated content may be incorrect." STYLE="height: 43px; width: 193px"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 23%; padding-right: 2pt; padding-left: 3pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 28%; padding-right: 2pt; padding-left: 3pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Goodwin
                                            Procter LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2929 Arch Street Suite&nbsp;#1700</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Philadelphia,&nbsp;Pennsylvania&nbsp;19104</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">August&nbsp;28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cognition Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2500 Westchester Ave.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Purchase, NY 10577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Re:&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Securities
Registered under Registration Statement on Form&nbsp;S-3</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as counsel to you in connection
with your filing of a Registration Statement on Form&nbsp;S-3 (File No.&nbsp;333-268992) (as amended or supplemented, the &ldquo;Registration
Statement&rdquo;) filed on December&nbsp;23, 2022 with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) pursuant
to the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), relating to the registration of the offer by Cognition Therapeutics,&nbsp;Inc.,
a Delaware corporation (the &ldquo;Company&rdquo;), of up to $200,000,000 of any combination of securities of the types specified therein.
The Registration Statement was declared effective by the Commission on January&nbsp;3, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reference is made to the opinion letter from Troutman
Pepper Hamilton Sanders LLP dated December&nbsp;23, 2022, and included as Exhibit&nbsp;5.1 to the Registration Statement. We are delivering
this supplemental opinion letter in connection with the prospectus supplement (the &ldquo;Prospectus Supplement&rdquo;) filed on August&nbsp;28,
2025, by the Company with the Commission pursuant to Rule&nbsp;424 under the Securities Act. The Prospectus Supplement relates to (i)&nbsp;the
offering by the Company of up to an aggregate of 14,700,000 shares (the &ldquo;Common Shares&rdquo;) of the Company&rsquo;s common stock,
par value $0.001 per share (the &ldquo;Common Stock&rdquo;), and (ii)&nbsp;the registration of placement agent warrants (the &ldquo;Placement
Agent Warrants&rdquo;) to purchase up to 514,500 shares of Common Stock (such shares issuable upon exercise of the Placement Agent Warrants,
the &ldquo;Placement Agent Warrant Shares&rdquo;) to be issued to the placement agent pursuant to the Placement Agency Agreement (as defined
below) covered by the Registration Statement. The Shares and Placement Agent Warrants are being sold and issued pursuant to (i)&nbsp;a
securities purchase agreement, dated as of August&nbsp;27, 2025 (the &ldquo;Securities Purchase Agreement&rdquo;), by and among the Company
and the purchasers signatory thereto (each, a &ldquo;Purchaser&rdquo; and, collectively, the &ldquo;Purchasers&rdquo;) and (ii)&nbsp;a
placement agency agreement by and between the Company and the placement agent signatory thereto (the &ldquo;Placement Agency Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have reviewed such documents and made such
examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification,
on certificates of public officials and, as to matters of fact material to the opinions set forth below, on certificates of officers of
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cognition Therapeutics,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August&nbsp;28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page&nbsp;2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The opinions set forth below are limited to the
Delaware General Corporation Law and, with respect to opinions paragraph 2, the law of the State of New York. Based on the foregoing,
we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Common Shares have been duly authorized and, when delivered and paid for in accordance with the terms
of the Securities Purchase Agreement, will be validly issued, fully paid and non-assessable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The Placement Agent Warrants have been duly authorized and executed by the Company and, when delivered
in exchange for the consideration set forth in accordance with the terms of the Placement Agency Agreement, will be valid and binding
obligations of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Assuming the Placement Agent Warrant Shares were issued today in accordance with the terms of the Placement
Agent Warrants, they would be validly issued, fully paid and non-assessable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The opinions expressed above are subject to bankruptcy,
insolvency, fraudulent transfers, reorganization, moratorium and other similar laws of general application affecting the rights and remedies
of creditors and to general principles of equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion letter and the opinion it contains
shall be interpreted in accordance with the Core Opinion Principles as published in 74 <I>Business Lawyer</I> 815 (Summer 2019).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the inclusion of this opinion
as Exhibit&nbsp;5.1 to the Registration Statement and to the references to our firm under the caption &ldquo;Legal Matters&rdquo; in the
Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under
Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Goodwin Procter LLP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">GOODWIN PROCTER LLP</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>tm2524576d2_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1<FONT STYLE="text-transform: uppercase">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of August&nbsp;27, 2025, between Cognition Therapeutics,&nbsp;Inc., a company incorporated
under the laws of Delaware (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages&nbsp;hereto (each,
including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, subject to
the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as
defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase
from the Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE,&nbsp;IN
CONSIDERATIO</B>N of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy
of which are hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Definitions</U>.
For all purposes of this Agreement, the following terms have the meanings set forth in this Section&nbsp;1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Acquiring Person</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;4.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule&nbsp;405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Auditor</U>&rdquo;
means Ernst&nbsp;&amp; Young, with offices located at 2005 Market St, Philadelphia, PA 19103.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section&nbsp;2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i)&nbsp;the Purchasers&rsquo; obligations to pay their respective Subscription Amount and (ii)&nbsp;the
Company&rsquo;s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first
(1<SUP>st</SUP>) Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Goodwin Procter LLP, with offices located at One Commerce Square, 2005 Market St 32nd Floor, Philadelphia, PA
19103.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i)&nbsp;if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m.&nbsp;(New York City
time) and before midnight (New York City time) on any Trading Day, 9:01 a.m.&nbsp;(New York City time) on the Trading Day immediately
following the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii)&nbsp;if this Agreement is
signed between midnight (New York City time) and 9:00 a.m.&nbsp;(New York City time) on any Trading Day, no later than 9:01 a.m.&nbsp;(New
York City time) on the date hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a)&nbsp;shares of Common Stock or options or other awards to employees, officers or directors
of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board
of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered
to the Company, (b)&nbsp;securities upon the exercise or exchange of or conversion of securities exercisable or exchangeable for or convertible
into shares of Common Stock issued and outstanding on the date of this Agreement, <U>provided</U> that such securities have not been amended
since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion
price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c)&nbsp;securities
issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, <U>provided</U>
that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule&nbsp;144) and carry no registration rights
that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section&nbsp;4.10(a)&nbsp;herein,
and <U>provided</U> that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through
its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide
to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is
issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
means (a)&nbsp;any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in
the ordinary course of business), (b)&nbsp;all guaranties, endorsements and other contingent obligations in respect of indebtedness of
others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except
guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;
and (c)&nbsp;the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with
GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Lock-Up
Agreement</U>&rdquo; means the Lock-Up Agreement, dated as of the date hereof, by and between the Company, on the one hand, and each of
the Company&rsquo;s directors and executive officers, in the form of <U>Exhibit&nbsp;A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section&nbsp;3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share
Purchase Price</U>&rdquo; equals $2.05 (or $2.049 in the case of the Pre-Funded Warrants), subject to adjustment for reverse and forward
stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means Titan Partners Group LLC, a division of American Capital Partners, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent Counsel</U>&rdquo; means McGuireWoods LLP, with offices located at 1251 Avenue of the Americas, 20th Floor, New York, NY 10020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means pre-funded warrants to purchase shares of Common Stock at an exercise price equal to $0.001 per share, in the
form attached hereto as <U>Exhibit&nbsp;B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final base prospectus filed with the Registration Statement, including all information, documents and exhibits filed with or
incorporated by reference into such base prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule&nbsp;424(b)&nbsp;of the Securities Act that is filed
with the Commission, including all information, documents and exhibits filed with or incorporated by reference into such prospectus supplement
and delivered by the Company to each Purchaser at the Closing, which shall be deemed to have occurred upon the filing thereof with the
Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;4.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission file No.&nbsp;333-268992 which registers the sale of the
Shares, the Pre-Funded Warrants and the Warrant Shares to the Purchasers, and includes any Rule&nbsp;462(b)&nbsp;Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;144</U>&rdquo;
means Rule&nbsp;144 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from
time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;424</U>&rdquo;
means Rule&nbsp;424 promulgated by the Commission pursuant to the Securities Act, as such Rule&nbsp;may be amended or interpreted from
time to time, or any similar rule&nbsp;or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;462(b)&nbsp;Registration
Statement</U>&rdquo; means any registration statement prepared by the Company registering additional securities, which was filed with
the Commission on or prior to the date hereof and became automatically effective pursuant to Rule&nbsp;462(b)&nbsp;promulgated by the
Commission pursuant to the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares and Pre-Funded Warrants to be purchased on the Closing Date pursuant to Section&nbsp;2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule&nbsp;200 of Regulation SHO under the Exchange Act (but shall not
be deemed to include locating and/or borrowing shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares (or Pre-Funded Warrants in lieu of Shares) purchased
hereunder as specified below such Purchaser&rsquo;s name on the signature page&nbsp;of this Agreement and next to the heading &ldquo;Subscription
Amount,&rdquo; in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise
price of the Pre-Funded Warrants, which amounts shall be paid as and when the Pre-Funded Warrants are exercised for cash).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means each subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, the Pink Open Market, OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Pre-Funded Warrants, the Lock-Up Agreements, all exhibits and schedules thereto and hereto
and any other documents or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, LLC, with offices located at 55 Challenger Rd, Ridgefield Park, NJ 07660, and any successor
transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock underlying the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally
and not jointly, agree to purchase, up to an aggregate of $15,067,500 of Shares; <FONT STYLE="font-size: 10pt"><U>provided</U>, <U>however</U>,
that, to the extent that a Purchaser determines, in its sole discretion, that such Purchaser (together with such Purchaser&rsquo;s Affiliates,
and any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s Affiliates) would beneficially own in excess
of the Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, in lieu of purchasing Shares such Purchaser may elect
to purchase Pre-Funded Warrants in lieu of Shares in such manner to result in the same aggregate purchase price being paid by such Purchaser
to the Company. The &ldquo;Beneficial Ownership Limitation&rdquo; shall be 4.99% (or, at the election of the Purchaser at Closing, 9.99%)
of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of the Securities on the Closing Date.
Each Purchaser&rsquo;s Subscription Amount shall be made available for &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;)
settlement with the Company or its designee(s). The Company shall deliver to each Purchaser its respective Securities, and the Company
and each Purchaser shall deliver the other items set forth in Section&nbsp;2.2 deliverable at the Closing. Upon satisfaction of the covenants
and conditions set forth in Sections 2.2 and 2.3, the Closing shall take place remotely by electronic transfer of the Closing documentation.
Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via DVP (i.e., on the Closing Date, the Company
shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released by the Transfer Agent directly to the account(s)&nbsp;at
the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver
such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer
to the Company) and settlement of the Pre-Funded Warrants shall occur by physical delivery by the Company to the Purchaser against payment
therefor. Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this Agreement by the Company
and an applicable Purchaser, through, and including the time immediately prior to the Closing (the &ldquo;<U>Pre-Settlement Period</U>&rdquo;),
such Purchaser sells to any Person all, or any portion, of the Securities to be issued hereunder to such Purchaser at the Closing (collectively,
the &ldquo;<U>Pre-Settlement Securities</U>&rdquo;), such Purchaser shall, automatically hereunder (without any additional required actions
by such Purchaser or the Company), be deemed to be unconditionally bound to purchase, such Pre-Settlement Securities at the Closing; <U>provided</U>,
that the Company shall not be required to deliver any Pre-Settlement Securities to such Purchaser prior to the Company&rsquo;s receipt
of the purchase price of such Pre-Settlement Securities hereunder; and <U>provided further</U> that the Company hereby acknowledges and
agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement
Period such Purchaser shall sell any shares of Common Stock to any Person and that any such decision to sell any shares of Common Stock
by such Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Deliverables</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
legal opinion of Company Counsel, including, without limitation, a negative assurance letter, in form and substance reasonably satisfactory
to the Placement Agent and Purchasers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
legal opinion of intellectual property legal counsel to the Company, including, without limitation, a negative assurance letter, in form
and substance reasonably satisfactory to the Placement Agent and Purchasers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Company&rsquo;s wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via The Depository
Trust Company&rsquo;s Deposit / Withdrawal at Custodian system Shares equal to the portion of such Purchaser&rsquo;s Subscription Amount
applicable to such Shares divided by the Per Share Purchase Price, registered in the name of such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Lock-Up Agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule&nbsp;172 under the Securities Act); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;for
each Purchaser of Pre-Funded Warrants, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares
of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to the Pre-Funded Warrant divided by the
Per Share Purchase Price minus $0.001, with an exercise price equal to $0.001, subject to adjustment as provided therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;such
Purchaser&rsquo;s Subscription Amount, which shall be made available for DVP settlement with the Company or its designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Closing
Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) when
made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless such representation or warranty
is made as of a specific date therein in which case they shall be accurate in all material respects (or, to the extent representations
or warranties are qualified by materiality, in all respects) as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
delivery by each Purchaser of the items set forth in Section&nbsp;2.2(b)&nbsp;of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless such
representation or warranty is made as of a specific date therein in which case they shall be accurate in all material respects, or to
the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
delivery by the Company of the items set forth in Section&nbsp;2.2(a)&nbsp;of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;there
shall have been no Material Adverse Effect with respect to the Company since the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude
in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of a Purchaser,
makes it impracticable or inadvisable to purchase the Securities at the Closing; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;after
giving effect to the issuance of the Shares pursuant to this Agreement, on the Closing Date, no fewer than 88,000,000 shares of Common
Stock shall have been issued and outstanding, and all such issued and outstanding shares of Common Stock shall have been issued prior
to or contemporaneously with the issuance of the Shares to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part
hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section
of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth in Schedule 21 to its most recent Annual Report on Form&nbsp;10-K.
The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any
Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable
and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references
to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to
own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, would not have or reasonably be expected
to result in: (i)&nbsp;a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii)&nbsp;a
material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company
and the Subsidiaries, taken as a whole, or (iii)&nbsp;a material adverse effect on the Company&rsquo;s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document (any of (i), (ii)&nbsp;or (iii), a &ldquo;<U>Material Adverse
Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke,
limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or
upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute
the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i)&nbsp;as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by
applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it
is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do
not and will not (i)&nbsp;conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles
of incorporation, bylaws or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute a default (or an event
that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii)&nbsp;subject to the receipt of Required Approvals,
conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations),
or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)&nbsp;and
(iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection
with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i)&nbsp;the filings required pursuant
to Section&nbsp;4.3 of this Agreement, (ii)&nbsp;the filing with the Commission of the Prospectus Supplement, (iii)&nbsp;application(s)&nbsp;or
notifications to each applicable Trading Market for the listing of the Shares or Warrant Shares for trading thereon in the time and manner
required thereby and (iv)&nbsp;such other filings as are required to be made under applicable state securities laws (collectively, the
&ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Issuance
of the Securities; Registration</U>. The Shares and the Warrant Shares are duly authorized and, when issued and paid for in accordance
with the applicable Transaction Documents (and in accordance with the applicable Pre-Funded Warrant, as the case may be), will be duly
and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its
duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Pre-Funded Warrants.
The Company has prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which became
effective on&nbsp;January&nbsp;3, 2023 (the &ldquo;<U>Effective Date</U>&rdquo;), including the Prospectus, and such amendments and supplements
thereto as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and
no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the Prospectus
has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened
by the Commission. The Company, if required by the rules&nbsp;and regulations of the Commission, shall file the Prospectus with the Commission
pursuant to Rule&nbsp;424(b). At the time the Registration Statement and any amendments thereto became effective, at the date of this
Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in all material respects
to the requirements of the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus and any amendments
or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was filed and at the Closing Date, conformed
and will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The Company was at the time of the filing of the Registration Statement eligible to use Form&nbsp;S-3.
The Company is eligible to use Form&nbsp;S-3 under the Securities Act and it meets the requirements set forth in General Instruction I.B.1
of Form&nbsp;S-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Capitalization</U>.
The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>, which <U>Schedule 3.1(g)</U>&nbsp;shall
also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof.
The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant
to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares of Common Stock to employees
pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents
outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal,
preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.
Except as set forth on <U>Schedule 3.1(g)</U>, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments
of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of
Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate
the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are
no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange
or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding
securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the
Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements
or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully
paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares
was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization
of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a
party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>SEC
Reports; Financial Statements</U>. The Company has filed or furnished all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;thereof,
for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material)
(the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus
and the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has
received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As
of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange
Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Company has never been an issuer subject to Rule&nbsp;144(i)&nbsp;under the Securities Act. The financial
statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the
rules&nbsp;and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been
prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved
(&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited
financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position
of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the
periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included within
the SEC Reports, (i)&nbsp;there has been no event, occurrence or development that has had or that could reasonably be expected to result
in a Material Adverse Effect, (ii)&nbsp;the Company has not incurred any material liabilities (contingent or otherwise) other than (A)&nbsp;trade
payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B)&nbsp;liabilities not required
to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii)&nbsp;the
Company has not altered its method of accounting, (iv)&nbsp;the Company has not declared or made any dividend or distribution of cash
or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock
and (v)&nbsp;the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company
stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except
for the issuance of the Securities contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no event, liability, fact,
circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company
or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required
to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been
publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Litigation</U>.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened
against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;).
None of the Actions set forth on <U>Schedule 3.1(j)</U>, (i)&nbsp;adversely affects or challenges the legality, validity or enforceability
of any of the Transaction Documents or the Securities or (ii)&nbsp;could, if there were an unfavorable decision, have or reasonably be
expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has
been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach
of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by
the Commission involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop
order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange
Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is threatened with respect to any of the employees of the
Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or any Subsidiary, and neither the
Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that
their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and
foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Compliance</U>.
Neither the Company nor any Subsidiary: (i)&nbsp;is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii)&nbsp;is in violation of any judgment, decree or order of any court, arbitrator or other governmental
authority or (iii)&nbsp;is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including
without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety,
product quality and safety and employment and labor matters, except in each case as would not have or reasonably be expected to result
in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Environmental
Laws</U>.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except as set forth on Schedule 3.1(m), (A)&nbsp;the Company is not in violation of any federal,
state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule&nbsp;of common law or any judicial or administrative
interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection
of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata)
or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants,
contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively,
&ldquo;<U>Hazardous Materials</U>&rdquo;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials (collectively, &ldquo;<U>Environmental Laws</U>&rdquo;), except for those violations that would not
reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (B)&nbsp;the Company has all permits, authorizations
and approvals required under any applicable Environmental Laws and is in compliance in all material respects with their requirements,
(C)&nbsp;there are no pending or, to the Company&rsquo;s knowledge, threatened administrative, regulatory or judicial actions, suits,
demands, demand letters, claims, liens, notices of noncompliance or violation, investigations or proceedings relating to any Environmental
Law against the Company, and (D)&nbsp;to the Company&rsquo;s knowledge, there are no events or circumstances that would reasonably be
expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental
body or agency, against or affecting the Company relating to Hazardous Materials or any Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good
and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each
case free and clear of all Liens, except for (i)&nbsp;Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii)&nbsp;Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which
is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Possession
of Intellectual Property</U>. The Company owns, possesses or has other rights to use all licenses, all patents, trademarks, service marks,
trade names, copyrights, software and design licenses, trade secrets, manufacturing processes, other intangible property rights and know-how
as are necessary for the conduct of its business as described in the SEC Reports (collectively, &ldquo;<U>Intellectual Property</U>&rdquo;),
except where the failure to own or possess such Intellectual Property would not reasonably be expected to have a Material Adverse Effect.
The Company has not received written notice of any infringement of or conflict with (and the Company does not know of any such infringement
of or conflict with) any asserted rights of others with respect to any Intellectual Property used by the Company that would reasonably
be expected to have a Material Adverse Effect. To the knowledge of the Company, all material Intellectual Property rights are enforceable
and there is no existing infringement by another Person of any of the Intellectual Property rights that would reasonably be expected to
have a Material Adverse Effect. The Company and its Subsidiary have taken reasonable security measures to protect the secrecy, confidentiality
and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited
to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company nor any Subsidiary
has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Transactions
With Affiliates and Employees</U>. None of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company,
none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other
than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing
of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending
of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any
entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder,
member or partner, in each case in excess of $120,000 other than for (i)&nbsp;payment of salary or consulting fees for services rendered,
(ii)&nbsp;reimbursement for expenses incurred on behalf of the Company and (iii)&nbsp;other employee benefits, including stock option
agreements under any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley
Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules&nbsp;and regulations promulgated by
the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain
a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii)&nbsp;transactions are recorded as necessary to permit preparation of
financial statements in conformity with GAAP and to maintain asset accountability, (iii)&nbsp;access to assets is permitted only in accordance
with management&rsquo;s general or specific authorization, and (iv)&nbsp;the recorded accountability for assets is compared with the existing
assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have
established disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for the Company and
the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company
in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified
in the Commission&rsquo;s rules&nbsp;and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure
controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report
under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic
report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures
based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over
financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or
is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Certain
Fees</U>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions are or will
be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section&nbsp;that
may be due in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities and application
of the proceeds thereof, will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company
Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo;
subject to registration under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Registration
Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any
securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the Exchange Act,
and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. The Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the
Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements
of such Trading Market</FONT> except for any such noncompliance <FONT STYLE="font-size: 10pt">which has been subsequently cured. The Company
is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance
requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established
clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing
corporation) in connection with such electronic transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations
or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s issuance of
the Securities and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the Purchasers
will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or
on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions
contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement
of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date
of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made and
when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with
respect to the transactions contemplated hereby other than those specifically set forth in Section&nbsp;3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section&nbsp;3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable stockholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder, (i)&nbsp;the fair saleable value of the Company&rsquo;s assets exceeds the
amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii)&nbsp;the Company&rsquo;s assets do not constitute unreasonably small capital to carry on
its business as now conducted and as proposed to be conducted in its SEC Reports including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (iii)&nbsp;the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate
all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect
of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such
debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has
no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy
or reorganization laws of any jurisdiction within one year from the Closing Date. The SEC Reports set forth as of the date hereof all
outstanding secured and unsecured Indebtedness of the Company or its Subsidiary, or for which the Company or its Subsidiary has commitments.
Neither the Company nor its Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Tax
Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material
Adverse Effect, the Company and its Subsidiaries each (i)&nbsp;has made or filed all United States federal, state and local income and
all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)&nbsp;has
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii)&nbsp;has set aside on its books provision reasonably adequate for the payment of all material taxes
for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no
basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i)&nbsp;directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)&nbsp;made any unlawful payment
to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds,
(iii)&nbsp;failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv)&nbsp;violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Accountants</U>.
The Company&rsquo;s accounting firm is the Auditor. To the knowledge and belief of the Company, such accounting firm (i)&nbsp;is a registered
public accounting firm as required by the Exchange Act and (ii)&nbsp;shall express its opinion with respect to the financial statements
to be included in the Company&rsquo;s Annual Report on Form&nbsp;10-K for the fiscal year ending December&nbsp;31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby.
The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except
for Sections 3.2 (f)&nbsp;and 4.12 hereof), it is understood and acknowledged by the Company that: (i)&nbsp;none of the Purchasers has
been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities
of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified
term; (ii)&nbsp;past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short
Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company&rsquo;s publicly-traded securities; (iii)&nbsp;any Purchaser, and counter-parties in &ldquo;derivative&rdquo;
transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the
Common Stock, and (iv)&nbsp;each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party
in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y)&nbsp;one or more Purchasers may
engage in hedging activities at various times during the period that the Securities are outstanding, and (z)&nbsp;such hedging activities
(if any) could reduce the value of the existing stockholders' equity interests in the Company at and after the time that the hedging
activities are being conducted.&nbsp; The Company acknowledges that such aforementioned hedging activities do not constitute a breach
of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Regulation
M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i)&nbsp;taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities, (ii)&nbsp;sold, bid for, purchased, or, paid any compensation for soliciting purchases of,
any of the Securities, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company, other than, in the case of clauses (ii)&nbsp;and (iii), compensation paid to the Placement Agent in connection
with the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>[Reserved</U>.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Stock
Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i)&nbsp;in accordance
with the terms of the Company&rsquo;s stock option plan and (ii)&nbsp;with an exercise price at least equal to the fair market value of
the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under
the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the
release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Cybersecurity</U>.&nbsp;
(i)(x)&nbsp;There has been no material security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees,
suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;<U>IT Systems
and Data</U>&rdquo;) and (y)&nbsp;the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition
that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii)&nbsp;the Company
and the Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules&nbsp;and regulations
of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy
and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation
or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii)&nbsp;the Company and the
Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information
and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv)&nbsp;the Company and the Subsidiaries
have implemented backup and disaster recovery technology consistent with industry standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee
or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section&nbsp;897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956,
as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to
regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(nn)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules&nbsp;and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or
any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(oo)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Health
Care Authorizations</U>. The Company has submitted and possesses, or qualifies for applicable exemptions to, such valid and current registrations,
listings, approvals, clearances, licenses, certificates, authorizations or permits and supplements or amendments thereto (collectively,
&ldquo;<U>Health Care Authorizations</U>&rdquo;) issued or required by the appropriate local, state, federal, national, supranational
or other foreign regulatory agencies or bodies (collectively, &ldquo;<U>Health Regulatory Agencies</U>&rdquo;) necessary to conduct its
business as described in the SEC Reports, including, without limitation, all such Health Care Authorizations required by the U.S. Food
and Drug Administration (&ldquo;<U>FDA</U>&rdquo;), the Australian Therapeutic Goods Administration (&ldquo;<U>TGA</U>&rdquo;), the Department
of Health and Human Services, the European Commission, the European Medicines Agency (&ldquo;<U>EMA</U>&rdquo;) or any other Health Regulatory
Agencies engaged in the regulation of Biologics (as defined in the Public Health Service Act of 1944, as amended (42 U.S.C. &sect; 201
et seq.)), except as would not be reasonably expected to result in a Material Adverse Effect. The Company has not received any written
notice of proceedings, or have any knowledge of any threatened proceedings, relating to the revocation or modification of, or non-compliance
with, any such Health Care Authorization, except where such revocation, modification or non-compliance would not result in a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(pp)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Compliance
with Health Care Laws</U>. The Company is, and has been, in compliance with all applicable Health Care Laws, and has not engaged in activities
which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid
or any other state, federal or national health care program, except where such noncompliance, false claims liability or civil penalties
would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect. For purposes of this Agreement,
&ldquo;<U>Health Care Laws</U>&rdquo; means all health care laws applicable to the Company which may include but are not limited to: the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), the Anti-Kickback Statute (42 U.S.C. &sect; 1320a-7b(b)), the
Civil Monetary Penalties Law (42 U.S.C. &sect; 1320a-7a), the Physician Payments Sunshine Act (42 U.S.C. &sect; 1320a-7h), the Civil False
Claims Act (31 U.S.C. &sect;3729 et seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal laws relating to
health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286-287, and the health care fraud criminal provisions under
the U.S. Health Insurance Portability and Accountability Act of 1996 (&ldquo;<U>HIPAA</U>&rsquo;) (42 U.S.C. &sect;1320d et seq.) as amended
by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.), the exclusion laws (42
U.S.C. &sect; 1320a-7), Basic Health and Human Services Policy for Protection of Human Research Subjects &ldquo;Common Rule&rdquo; as
codified and enforced by the Department of Health and Human Services in 45 C.F.R. part 46 and enforced by FDA under 21 C.F.R. Part&nbsp;50,
Laboratory Animal Welfare Act of 1966, Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act),
any and all other applicable comparable local, state, federal, national, supranational and foreign health care laws and the regulations
promulgated pursuant to such laws, each as amended from time to time. The Company has not received written notice of any claim, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or Governmental Authority
with jurisdiction over the Company or third party alleging that any product operation or activity is in material violation of any Health
Care Laws, and, to the knowledge of the Company, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration
or other action is threatened. The Company has not received any written notice of adverse filing, warning letter, untitled letter or other
correspondence or notice from the FDA, the European Commission, the EMA, the TGA or any other Health Regulatory Agencies, or any other
court or arbitrator, alleging or asserting material noncompliance with Health Care Laws. The Company is not a party to and has no ongoing
reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent
decrees, settlement orders, plans of correction or similar agreements with or imposed by any Governmental Authority with jurisdiction
over the Company. Additionally, neither the Company, nor, to the knowledge of the Company, any of its employees, officers or directors
has been excluded, suspended or debarred from participation in any U.S. federal health care program or human research study or trial or,
to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably
be expected to result in debarment, suspension or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(qq)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Health
Care Products Manufacturing</U>. The manufacture of the Company&rsquo;s products candidates by or on behalf of the Company, to the knowledge
of the Company, is being conducted in compliance with all applicable Health Care Laws, including, without limitation, the FDA&rsquo;s
regulation pertaining to Biologics at 21 CFR Part&nbsp;600, and, to the extent applicable, the respective counterparts thereof promulgated
by the European Commission, the EMA, TGA or other Health Regulatory Agencies. Except as set forth on <U>Schedule 3.1(qq)</U>, the Company
has not had any manufacturing site (whether owned by the Company or, to the knowledge of the Company, that of a third party manufacturer
for the Company&rsquo;s products) subject to an FDA, European Commission, EMA, TGA or other Health Regulatory Agency shutdown or import
or export prohibition, nor received any written FDA, European Commission, EMA or other Health Regulatory Agency &ldquo;warning letters,&rdquo;
or &ldquo;untitled letters&rdquo; alleging or asserting material noncompliance with any applicable Health Care Laws, requests to make
material changes to the Company&rsquo;s products, processes or operations, or similar written correspondence or notice from the FDA, the
European Commission, the EMA, the TGA or other Health Regulatory Agency alleging or asserting material noncompliance with any applicable
Health Care Laws, other than those that have been satisfactorily addressed and/or closed with the FDA, the European Commission, the EMA
or other Health Regulatory Agency. To the knowledge of the Company, none of the FDA, the European Commission, the EMA, the TGA or any
other Health Regulatory Agency is considering such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(rr)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Research
Studies and Trials</U>. (A)&nbsp;The research studies and trials conducted by or, to the Company's knowledge, on behalf of, or sponsored
by, the Company, or in which the Company has participated, that are described in the SEC reports, or the results of which are referred
to in the SEC Reports, as applicable, were and, if still pending, are being, conducted in all material respects in accordance with applicable
experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products
or product candidates comparable to those being developed by the Company and all applicable statutes, rules&nbsp;and regulations of the
FDA, National Institute of Health, Department of Health and Human Services, the European Commission, the EMA, the TGA and any other Health
Regulatory Agencies to which it is subject; (B)&nbsp;the descriptions of the results of such studies and trials contained in the SEC Reports
do not contain any misstatement of a material fact or omit to state a material fact necessary to make such statements not misleading;
(C)&nbsp;the Company has no knowledge of any research studies or trials not described in the SEC Reports the results of which reasonably
call into question in any material respect the results of the research studies and trials described in the SEC Reports; (D)&nbsp;the Company
has not received any written notices or correspondence from the FDA, the European Commission, the EMA, the TGA or any Health Regulatory
Agency or any institutional review board or comparable authority requiring or threatening the premature termination, suspension, material
modification or clinical hold of any research studies or trials conducted by or on behalf of, or sponsored by, the Company or in which
the Company has participated that are described in the SEC Reports, and, to the Company's knowledge, there are no reasonable grounds for
the same; (E)&nbsp;there has not been any violation of applicable Law or regulation by the Company in any of its product development efforts,
submissions or reports to the FDA, the European Commission, the EMA, the TGA or any other Health Regulatory Agency that could reasonably
be expected to require investigation, corrective action or result in enforcement action, except where such violation would not, singly
or in the aggregate, result in a Material Adverse Effect; and (F)&nbsp;the research studies and clinical trials of Company are being conducted
in an ethical and human manner under state, national or supra-national applicable Laws that are either equal or more stringent than applicable
Laws and regulations enforced by the Department of Health and Human Services and FDA governing human, animal or non-human primate research
participants and test subjects and such studies and the clinical trials are conducted, where applicable, under the auspices of a neutral
and independent Institutional Animal Care and Use Committee or institutional review board and applicable state, national, or supra national
agencies responsible for oversight.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i)&nbsp;as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii)&nbsp;as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by
applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Understandings
or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty
not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it exercises any Pre-Funded Warrants it will be, an &ldquo;accredited investor&rdquo; as defined in Rule&nbsp;501(a)(1), (a)(2), (a)(3),
(a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded, (i)&nbsp;the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii)&nbsp;access to information about the Company and its financial condition,
results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii)&nbsp;the
opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that
is necessary to make an informed investment decision with respect to the investment.&nbsp; Such Purchaser acknowledges and agrees that
neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect
to the Securities nor is such information or advice necessary or desired.&nbsp; Neither the Placement Agent nor any Affiliate has made
or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired
non-public information with respect to the Company which such Purchaser agrees need not be provided to it.&nbsp; In connection with the
issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or
fiduciary to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser first
received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material pricing
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other
than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acknowledges and agrees that the representations
contained in this Section&nbsp;3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on the Company&rsquo;s representations
and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other
document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated
hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty,
or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Furnishing
of Information</U>. Until the time that no Purchaser owns Securities or Warrant Shares, the Company covenants to maintain the registration
of the Common Stock under Section&nbsp;12(b)&nbsp;or 12(g)&nbsp;of the Exchange Act and to timely file (or obtain extensions in respect
thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to
the Exchange Act, even if the Company is not then subject to the reporting requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2
of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules&nbsp;and regulations
of any Trading Market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder
approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Securities
Laws Disclosure; Publicity</U>. The Company shall (a)&nbsp;by the Disclosure Time, issue a press release disclosing the material terms
of the transactions contemplated hereby, and (b)&nbsp;file a Current Report on Form&nbsp;8-K, including any Transaction Documents required
to be filed as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such
press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered
to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates
or agents, including, without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents.
In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or
similar obligations under any agreement, whether written or oral, entered into in connection with the transactions contemplated by this
Agreement between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees, Affiliates or
agents, including without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any of their Affiliates on the
other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult with each
other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser
shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect
to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company,
which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing
party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing,
the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission
or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a)&nbsp;as required by federal
securities law in connection with the filing of any Transaction Documents with the Commission and (b)&nbsp;to the extent such disclosure
is required by law or Trading Market regulations, in which case the Company shall provide the Placement Agent and each Purchaser with
prior notice of such disclosure permitted under this clause (a)&nbsp;or (b)&nbsp;and reasonably cooperate with the Placement Agent and
each such Purchaser regarding such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Stockholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser
is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section&nbsp;4.3, the Company covenants and agrees that neither it, nor any other Person acting on
its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes
constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such
information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company,
any of its Subsidiaries, or any of their respective officers, directors, employees or Affiliates delivers any material, non-public information
to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any
duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates
or agents, including, without limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of their respective
officers, directors, employees, Affiliates or agents including, without limitation, the Placement Agent, not to trade on the basis of,
such material, non-public information, <U>provided</U> that the Purchaser shall remain subject to applicable law. To the extent that any
notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file or furnish such notice with the Commission
pursuant to a Current Report on Form&nbsp;8-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing
covenant in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Use
of Proceeds</U>. Except as set forth on <U>Schedule 4.6</U> attached herein, the Company shall use the net proceeds from the sale of the
Securities hereunder for working capital purposes and shall not use such proceeds: (a)&nbsp;for the satisfaction of any portion of the
Company&rsquo;s debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices),
(b)&nbsp;for the redemption of any Common Stock or Common Stock Equivalents, (c)&nbsp;for the settlement of any outstanding litigation
or (d)&nbsp;in violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section&nbsp;4.7, the Company will indemnify and hold each Purchaser and its directors,
officers, stockholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning
of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers, stockholders, agents,
members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur
as a result of or relating to (a)&nbsp;any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents or (b)&nbsp;any action instituted against the Purchaser Parties in any capacity,
or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with
respect to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach
of such Purchaser Party&rsquo;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings
such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws
or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct.
If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such
Purchaser Party shall promptly notify the Company in writing, and, the Company shall have the right to assume the defense thereof with
counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of
such Purchaser Party except to the extent that (i)&nbsp;the employment thereof has been specifically authorized by the Company in writing,
(ii)&nbsp;the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii)&nbsp;in such
action there is, in the reasonable opinion of counsel a material conflict on any material issue between the position of the Company and
the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than
one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y)&nbsp;for any settlement by a
Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; or (z)&nbsp;to
the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of any
of the representations in the Transaction Documents. The indemnification required by this Section&nbsp;4.7 shall be made by periodic payments
of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity
agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or
others and any liabilities the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Listing
of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the Trading
Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares
and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market.
The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in
such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and
Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably
necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s
reporting, filing and other obligations under the bylaws or rules&nbsp;of the Trading Market. The Company agrees to maintain the eligibility
of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including,
without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection
with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Securities</U>.
The Securities shall be issued free of legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Subsequent
Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;From
the date hereof until sixty (60) days after the Closing Date, neither the Company nor any Subsidiary shall (i)&nbsp;issue, enter into
any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii)&nbsp;file
any registration statement or amendment or supplement thereto, other than the Prospectus Supplement or filing a registration statement
on Form&nbsp;S-8 in connection with any employee benefit plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
the foregoing, this Section&nbsp;4.10 shall not apply in respect of an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is
also offered to all of the parties to such Transaction Document. For clarification purposes, this provision constitutes a separate right
granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers
as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition
or voting of Securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it
nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short
Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such time
that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section&nbsp;4.3.&nbsp; Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section&nbsp;4.3, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information
included in the Disclosure Schedules (other than as disclosed to its legal and other representatives).&nbsp; Notwithstanding the foregoing,
and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i)&nbsp;no
Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of
the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial
press release as described in Section&nbsp;4.3, (ii)&nbsp;no Purchaser shall be restricted or prohibited from effecting any transactions
in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated
by this Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.3 and (iii)&nbsp;no
Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries,
or any of their respective officers, directors, employees, Affiliates or agent, including without limitation, the Placement Agent, after
the issuance of the initial press release as described in Section&nbsp;4.3.&nbsp; Notwithstanding the foregoing, in the case of a Purchaser
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the
portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Lock-Up
Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to extend
the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party to
a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek specific performance
of the terms of such Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Pre-Funded Warrants set forth the totality of the procedures required of
the Purchasers in order to exercise the Pre-Funded Warrants. No additional legal opinion, other information or instructions shall be required
of the Purchasers to exercise their Pre-Funded Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required
in order to exercise the Pre-Funded Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance
with the terms, conditions and time periods set forth in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE&nbsp;V.</B><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination</U>.&nbsp;
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties hereto, if the Closing has not
been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that
no such termination will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party hereto shall pay the fees and
expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including,
without limitation, any fees required for same-day processing of any instruction letter delivered by the Company), stamp taxes and other
taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents,
exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered via
email attachment at the email address as set forth on the signature pages&nbsp;attached hereto at or prior to 5:30 p.m.&nbsp;(New York
City time) on a Trading Day, (b)&nbsp;the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages&nbsp;attached hereto on a day that is not a Trading Day
or later than 5:30 p.m.&nbsp;(New York City time) on any Trading Day, (c)&nbsp;the second (2<SUP>nd</SUP>) Trading Day following the date
of mailing, if sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom such
notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages&nbsp;attached
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Securities based on the initial
Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against
whom enforcement of any such waived provision is sought, <U>provided</U> that if any amendment, modification or waiver disproportionately
and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers)
shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed
to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement
hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser
relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected
Purchaser. Any amendment effected in accordance with this Section&nbsp;5.5 shall be binding upon each Purchaser and holder of Securities
and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other
than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or
transfers any Securities, <U>provided</U> that such transferee agrees in writing to be bound, with respect to the transferred Securities,
by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations and warranties of the Company
in Section&nbsp;3.1 and the representations and warranties of the Purchasers in Section&nbsp;3.2. This Agreement is intended for the benefit
of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof
be enforced by, any other Person, except as otherwise set forth in Section&nbsp;4.7 and this Section&nbsp;5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, stockholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such
court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section&nbsp;4.7,
the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act,
the Electronic Signatures and Records Act or other applicable law, e.g., <U>www.docusign.com</U>), such signature shall create a valid
and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such
&ldquo;.pdf&rdquo; signature page&nbsp;were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Rescission
and Withdrawal Right</U><FONT STYLE="font-size: 10pt">. Notwithstanding anything to the contrary contained in (and without limiting any
similar provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under
a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such
Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand
or election in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the case
of a rescission by a Purchaser of an exercise of an Pre-Funded Warrant, such Purchaser shall be required to return any Warrant Shares
subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the
Company for such Warrant Shares and the restoration of such Purchaser&rsquo;s right to acquire such Warrant Shares pursuant to such Purchaser&rsquo;s
Pre-Funded Warrant (including, if applicable, issuance of a replacement Pre-Funded Warrant evidencing such restored right)</FONT><U>.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, the Company shall issue
or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft
or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs
(including customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby
agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would
be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser
enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part
thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required
to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without
limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration
the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such
payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several and
not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For
reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through
Placement Agent Counsel. Placement Agent Counsel does not represent any of the Purchasers and only represents the Placement Agent. The
Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not
because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained
in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and
the Purchasers collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Saturdays,
Sundays, Holidays,&nbsp;etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule&nbsp;of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference
to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.20&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>WAIVER
OF JURY TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH
KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,&nbsp;IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages&nbsp;Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">Cognition Therapeutics,&nbsp;Inc. &nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><U>Address for Notice:</U></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">E-Mail:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">With a copy to (which shall not constitute notice): </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 1in">[PURCHASER SIGNATURE PAGES TO
SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Purchaser: ________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Purchaser</I>:
_________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: _______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address of Authorized Signatory: _________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Securities to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-Funded Warrants: ___________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: ____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding anything contained in this Agreement to the contrary, by checking
this box (i)&nbsp;the obligations of the above-signed to purchase the securities set forth in this Agreement to be purchased from the
Company by the above-signed, and the obligations of the Company to sell such securities to the above-signed, shall be unconditional and
all conditions to Closing shall be disregarded, (ii)&nbsp;the Closing shall occur on the first (1<SUP>st</SUP>) Trading Day following
the date of this Agreement and (iii)&nbsp;any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause
(i)&nbsp;above) that required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase
price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the above-signed
(as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on
the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Form&nbsp;of
Lock-Up Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Form&nbsp;of
PRE-FUNDED WARRANT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cgtx-20250827.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaiFSbOdzZR+qYkxtmB/bRk6Hy0kw45oRCzNX3zmwXYF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:cgtx="http://cogrx.com/20250827" elementFormDefault="qualified" targetNamespace="http://cogrx.com/20250827">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://cogrx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20250827_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cgtx-20250827_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>cgtx-20250827_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>cgtx-20250827_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="cgtx-20250827.xsd#Cover" roleURI="http://cogrx.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cogrx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2524576d2_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2524576d2_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  K ,$# 2(  A$! Q$!_\0
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MO#EOK%]%<7$L@6--I1>-W.>M<UXM32K>U@M-/$(EC?+A.2!CN:JO"5W)O06
MKTX\L(QU>[(/  _XGTO_ %P/\Q7HU>=^ O\ D.R_]<#_ #%>B5T8;X#DS/\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 27, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 27,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cognition
Therapeutics,&#160;Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001455365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4365359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2500 Westchester Ave.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Purchase<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">481-2210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001  par value&#8239;per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CGTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2524576d2_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cogrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cgtx-20250827.xsd</File>
    <File>cgtx-20250827_lab.xml</File>
    <File>cgtx-20250827_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2524576d2_8k.htm">tm2524576d2_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2524576d2_8k.htm": {
   "nsprefix": "cgtx",
   "nsuri": "http://cogrx.com/20250827",
   "dts": {
    "schema": {
     "local": [
      "cgtx-20250827.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cgtx-20250827_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cgtx-20250827_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2524576d2_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://cogrx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-08-27",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2524576d2_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-08-27",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2524576d2_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cogrx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001104659-25-084845-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-084845-xbrl.zip
M4$L#!!0    ( $V)'%MNT%^=)P,  -D+   1    8V=T>"TR,#(U,#@R-RYX
M<V2U5MMRVC 0?>],_T'U:\8W*+D02"8E0\L,23K0I"0O'6$+1X,M.9(<._GZ
M2KYQ,;A 6Y[DW7/.[GIW93J72>"#5\0XIJ2KV8:E 40<ZF+B=;7[L7XU[@T&
M&KB\^/@!R%_GDZZ#/D:^VP;7U-$'9$;/P2T,4!M\100Q*"@[!P_0CY2%]K&/
M&.C1(/210-*116J#8\.> EW?0?8!$9>R^]&@E'T6(N1MTXSCV"#T%<:4S;GA
MT& WP;& (N*EFI58^6\W^@WF3DD^@E>M^"09X8F'R&DTA,TGYR?$_?'TSGU_
M&AV]/,X3$7PQIZ/Y\;<W:QY_;M%1[_UVTGP/XLEC/PO9X<XS"B"0O2"\JZGZ
M\O+BID&99S8LRS8G-\-QBM,R8#OQ,9EO@MMG9V=FZBV@%60R97XAW325>PHY
M*I6E%]?@,>$"$F<%[XJ2L QNF9ES!8HW0H\S*"Z@+EK#<>08'GTUI4/B&ZT"
M&''=@S LP3/(IZEH[E@!<R:J0&E<!^GB+41\(S1SK1 <3R0EUJ$>2]1 IA#K
MM'$BM\I' 2*B3UEPC68P\F46+Q'T\0PC5P,",@\)-6$\A ZJDRIF%!)"Y2C+
M=<HMRA:&6,YJ:9 FU=LVHS[Z(9,&ZB!W:8.^\I@]*N\"#6"WJV7'):5"RT4S
M3' :-U\<&^AJ32)5H#RFS(ZY#JXJ11RY=^0B/8<,<4E/ZQE*0\[/(?5<!_I.
MY!]$7>17Q\SMQ5NLO-YB?T9H!M*]:ZL)Z6H<JXM/RVW/#,VZFIH4O6CF+UFV
M(2>H@*@(-7N7]FC]3>6!"PG(G(I*Y5Z0(C1$3& YQDO+GZ6.A:)_7PH#5!RN
M ?,?5N[#Z;Z52PKR_V/)0Z5?K;5CKJZ5?%Y?O8XLES(!2&6!ZR[/[-H?4B>5
MJJ&H)[W@Z<JDVPV]:1L)=Q>9[I/$X@WLET3!.R")+5?XIOA\&UP=TA':->B6
M3T%MT(T<$_F"%Y:#4UC^</Q%#JG,7DFLM-,5S%022O2S;MFRB=O3^1,S?>8'
M#8%#(R+8VSZ#L$PI'@[KQN*3OULC"GS6!/4OX-"P!TQ!-?BF$>B8F9H\_@90
M2P,$%     @ 38D<6WRC3L#]"@  ?X8  !4   !C9W1X+3(P,C4P.#(W7VQA
M8BYX;6S-G5UOX[@5AN\+]#^P[DT+C.-Q@ET@V<DN,IYD86PV26//;-M%L: E
MQA%"DP$E)_:_+RF)LD3Q2$J*DIR+&8_X'NJE^)BDOHX__;3;4/1"1)IP=CZ:
M'GT<(<(B'B=L?3[ZNAA?+&;S^0BE&68QIIR1\Q'CHY]^_/.?D/SSZ2_C,;I*
M"(W/T!<>C>?L@?^ ;O"&G*&?"2,"9US\@+YANE5;^%5"B4 SOGFF)".RH-CQ
M&?K^:+I"X_& :K\1%G/Q]7Y>5?N89<_IV63R^OIZQ/@+?N7B*3V*^&98A8L,
M9]NTJNWC[F/YIPC_1!/V=*;^6N&4('FX6'JV2Y/SD=ION=O7DR,NUI/CCQ^G
MDW_^>KV('LD&CQ.F#EM$1CI*U6*+FYZ>GD[R4BUM*7<K0?4^3B;:3E6S+$TZ
M]#4G:7*6YO:N>82SO-=[=X- A?K?6,O&:M-X>CP^F1[MTGBD#WY^! 6GY)X\
MH+R99]G^69*4)@J$4;GM49 'NQDJQ$3%3QA9XXS$:D>G:D?3[]6._EINOL8K
M0D=(*24?8+M.&W6501/79N^(2'A\R=[GVHSV9%]^=T3V/S2@'N^\"4N>8?HN
M\_5(Y[9OR/N.^"'._9&6PSQYWY&N1?Y?;&=MRV\^O/;C2M7&:_FI89'L,CF!
MD5B;5%5TC,#Y'O*)H:R[JIU'C7JI&LVY:+==S8QYG2F)CM;\91*31-9]_)WZ
M,%8?\F;+__PQXW(A<+%*,X&C3->4-^-\9"F?F):4\D)H7UA$/8TK%9.(RZGI
M.1O3XC 6X0^";ZR[+5O-+85_T%457QP6N0O :$,F2,JW(B)OZI6Z6^@HE8XV
M5"K4BHJP\=?%Z,=<@W[7JO]\FAQJ<=#1<@FTW1"6+66-EA8TBUUUL\V4[N5Z
M61"=;#%D]K&6(*5QW,$7<L>QVOD5Q6N+?:/<51=;;>D^;A0&T<DV1V8O5QJD
M1+ZZ^0M)(Y$\J^5\5SL:,N>=;C'9ZON:)BP$VL9@$FI:3P/[/5DG:FI1%M3Y
M+5$;.X8Q0.]ZZ.^T;<X%5G$0T QQ",X6]2!417GBZ(*Q+:;WY)F++GR:,M?4
MV$R:L-0U03%B,0:B46A1(?9$Q#^V\HR="+KOA:*E=,T%8-5$PY %18?=&PA(
M)??+R%)@EB9J .N%I"UU?KH!F&V=>ABZH#@!S,&G))7>+RF+1T*INAV 6?^
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M]W0A50WX?260]Q^8O*N\(6'^.R/*4,77$-)'8B#L/S%A>QPB\7Y01&CF^$"
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MQE 1IHO.D:\;N\&]F;;XQOUR;U^U6_X'4$L#!!0    ( $V)'%NL0\+1NQ4
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M&WM"K8+\H@#KN\80]5HW[L-INL$=D\Y.B&5;#)\9TQ/44>:"XHL/AJXS"ZT
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MF[D5?D]' Y;MA@;N8Z:H Z%[V9'Q?\R]_O+PEV)_??J1&#5Q["*]+IX&G$R
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M+]5U!Z=:L7,:>#&+144^88?Q/^T\]SC?B;J*0='OU;1;DCWUO0^:/MB: _9
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MZT,CE%K34/J!<<#BWK<URK*O@(@.[I&2JI%P^L 9X(_'>"VPG@]G+X#U<G6
M:A%K=4)ZJ-^0'D2'; DY->0V*VD6-E!<[S]9RTZM^8%RM:WX!KO8B02#W+R9
MC@I0<^:2\1^$W;3:6<;40@H('1U%1DC0#R99'5RT""\P(>-^K9T5E-;;/!B"
MB>CVMAD_7457&/&--:=)"H<'C[T:07MO<=MR3P%NXFGW!G/09OR8*->815_3
M96^XY>2".EM87?'^JA??(I#X0NG]L5O3^#75JT[&!^Y:EZ$XI,7;1=J[B[C6
M\DT*&VI&RR+T(6:A$MRX0[+9MVA:RW5QM ><T&GC[(7RYTSI<8+J.I\G>+,N
M=C/10<*HR_X*$'O@D,.VXFUL")&M"$IVD.W/,2[&IHV_A4IFKV.4M.YL)(CY
M#)F?7_ZTJY8[BQU^;LO9O ?4+@=._#$.K%688#-06].P_TH*QUQ[(+B&\>[V
M[*RYVVR4^XU@)VU<?*RE]8^MYZVO%B/LNK2]"VX+$D#)!E"BX*Q!<N>Q>X#N
M1.RXFV_!=A$#Q7"C!4HBP-J+W*8/<'>L["*EZ]]T0O=K (;GUM D1^M6[&Z^
MR%)[74&S#30S/&K4G"UJYY $],(D0F@N_=($_#-*WW O61%=HT%'1K5N&\V#
M0\O3G=R#R#CLXG'^'NC3L]'Y.3"TX^.3#\?<'.)\<RN(-I5* D:V-JCUTM.!
M3^@)KKS#FP_ESLVP.JXCO=_%B/*,]=_ AU=Z)UZZ\=T%)9#@LFQXNK#UK6B\
M7YMID7!%$)4#\)7O%)8N$WNW1JT@PYOWJ;DNEGII+SSX'4@":(7OH?5YB]3U
MF%LRBQ?@KT"S5FSY-MR["<V>.30[GPR/WYY/QD='_-5'=EH+ ]CDM5Z+-[H,
MK*"^1AIW%<D7O'WT9WOY:!<BIN) #ZP D!HVA]2FQUH7E"M@DDN^*!+/GEM'
M&PN1#O0(6U I:)V"V&'>!+741/^1_Y+MPL9M0BR",-!$?R,;!.W1\,6QI>ML
M _^-Z'XF-0XF\;5(J):*E1CD</F:/=FTN[B*D^'LM57B%P0^J [YZ@GJK=/F
M6O.96(WU!"E9=,-'T0!)H)2T7S=-SKA,;J!R7<WI=A%?OI$')0"-Y((P&BS1
M[9S[NBRY2\<<@!A7Z-66/"4G4F3# V["N="_8U[P2DQAK#I)M]V%L?:F$_FM
MI<J%; 8[B'TN>$W3D2,5&+X+(1C=[PXT.;#^DX*TBN9*>>GV:G+7FZ=9;NKT
MI>#&+!+1I-W8"Z1A*)<D2$G@2)N8G6,=C^YE=^LTUXGZ][3MB^9>+A-V7<"2
M:H=L,Y*0EU:ESV%/ZVI; ^OJ#<NY+7VPIWIMD/4S ">(-M4_2#M43*_@QX(+
MT1N7(;/6&IO@80L^:A064>6BP) OY*Z#4;Y;'WDK(/*6'DK,%8KE/.';$0!S
MIO;^W<>R++JO(68>BTZAEFD:6F*XLSH1R?'4+Y]I*X1DR><4OQ!'6L;0$?"U
M(G&6$G$HX%11O;Z><O6E@<(Z"<48G,/L*"H<Z>(#@Z ^.8RA^#2HW 1Y<<+/
M[)7+B#;N4<O.MC0Z"V:V,M0GF>P]>_:8]5"=Y^CGJK-?[DHDR[!7W3J#D!-]
M.#@ALJ&#>7<I0,&MZ+!GJKLA7.,[NYM-YO:>L762N.A"0%(N>.88-@M%ZL,U
MY1BY.N56/UN^RH$;![F^03/WT&-7)32P44?*8*;@*:!(HSYE0(X'SOBCH%30
M: @5*)LG21W3.13EK:!B!;\CX "=G%?$IQ)VM482 +A:4/>$3UAVC:T;W5U]
M],8V\9V!'5_P!2X^.<;U6JY%I]'$=U?5>+ICNN&0IL-5?U.1;9QF!0#,B0ED
M!"V]3$INY$RBCQM8K<25Q$,$1B/=UWPEJ>;HRO3.Q^_%"HI(-WOT^O_NCU^?
MM[BRV.(MT*?S_^[OGFX7''OQ(SCVT()CIW/2(B0/S)O;P94$49;+K63 [PKK
MR*B"&!7*2'1I6%<AJ.^5=-=LK4>VL3/I8$2)#^O)HG\>M4R&;XY&"N-\YZ?#
M@_'QN_]\M/N(_CX=OGUK__[J2:^3N+S$1W?_[M ] O+7RP(0TWYZ1/BT/SFS
M$Y"&&NFY/2] VD<6YR9OPV5L%\F_#*\%D#?L7D*_SO0"V//+FY:Y-M)O& @J
M<S1'5MB)>2 -3/:?3-[B_YW=T8KM*?R/1K6?[H#3O7D]&4^&Q^IT>#8Y'IV=
MJW=G)Q].L;IG@)8CH\G=3394P$3&Y^.38W5RJ(;O1V?C YC]8'@*JSARJZ#R
M(CM_ TA/"&-?_Z %?DH&_^GO=TD%;U8O0[Q?FW2S_'([?O;B3E?UI'C2[PUC
MO5#GP%F+C2N4%3S?_?NWTEKPMO_R[C9U#&;Q2W7#KN[W%B;8EA7V8"L08G46
MA/.OS%=LZ0=QW_7A[']X/0Q"-1RE>8ENX&^3;/=%@C6N]'X'ENR2Q!<&^A*?
MZC-<P.L1/'H@9IE]9<!+(8%SA\+NF?J8Y?.8"I7!GB3+:*">_@+ZXN$\R_([
MG2S(4OZ$J+C[XDZ''Y;2(;C.J.YPAA&&/5_:&.)_E7BH2SF@BWRY$V6+OU85
MN .@48*W^%2'7%Z'?@#G^B#O)U@:1>F"+W0]U#WN1THZW,')N^,QAIG4Y-?1
MV?!T]&$R/C@?\%3CXX,=KSC^N_-QIXU@^\3M8JG1<Y!FU[E>NAG_'30W/D+0
MW]114FAUED38'SU.'I(*=XN=W>]MB!K'?1)'KLN7]$F\'TK<'3"P-GT(U:%[
MS78/,-6'W-232P/<P\#91(7EN6ETEPZBI\]W=]5'4Y31)89T<C6\NM,,"1NT
M$F7E^8L7=REUO:K2),@[FT.4E7ENQ_ZO*+O(OU@EY;[BT&V\VO_\X=7^#KW:
M-NX"RIEOVO?G:F%_V@: :BER1\T.P90[Y>SR^[V;VQ'7+S^(Z_LF+JR2"OMH
M#MF-<I\QLV,OH=)(#U D'&LI7JIJN30Y9DH^>GT(7T@3WEGMSH3UQ!.G']Y7
M2-R.1O=V?Q#IPR+2-]\KD>+=@#S1R:$Z.CGX[^T/I\I59][?W=R2T/9^$-K#
M(K2#[Y70_F?2D*[PE*J&<W7ZX>S@U^'Y2'T<GIT-D3P?ACA\^DJ=<.XW&-0:
M5/-[0[1_'04]>7/R]A.ZLY[\.GE_]/K_ U!+ P04    " !-B1Q;QR).: :8
M   I P, %@   '1M,C4R-#4W-F0R7V5X,3 M,2YH=&WLO>MRVU:V+OI?57H'
MG#YK]Y:J8$62G5L[)U6R+2?>*[&];6?UZCIU?H D*"(& 08 I;"?_HSKG&,"
M$Q1M2]F*XE6U.A8) A/S,J[?^,9W/[[[^:?O]_>^^_'\[!G\-\'_^^[=BW<_
MG7__W1?\7_CV"_GZNR>OGOTK>?ON7S^=_S]_F]=5]X_DY'C5)>^*9=XF+_.K
MY$V]S*J4/TB3MWE3S/\&/X2?OO[0WSU.EEES453_2/#2X\=)E__>/<C*X@(^
MFN95ES=_^_Z[YZ]>OM,[TP5=DU7MO&Z6_TC6JU7>3+,VA^N>?/_W:M*N'G_W
MQ1-X,_P5_.?U;0RM*2X6'3WQ_/=%,2DZN.'1R:X#U5'*")_<UBCO\ 1^Q-#>
MGC_]Y<V+=R_.W^[OO?[ES=,?S]Z>)V<_O#D___G\Y;O;&+)?J5N9@U_7;5?,
M-_)A4<URO.GQT9=%];?OWRV*%NXQ73=%5\ #7J^;Z0*F(CF[:/)\"9?N[QUT
M>-'?R]EOZ_KQ=[]\[[[Z[HM?OO][0Q\?)G#)+.OR69*U23U/SM87\%Q^L=.O
MT^3T^/3+-)GDW56>5\G3^J*"!]95\FZ1-]DJ7W?%M$WY\A?5]"A-LF1:+U=9
MM4F*:EHWJ[K!N^_OK>$%FJ1;Y$F97=&CGN7PKZS)DP/\U(_S*?_>CA)N6\V2
M/)LNDI6\:9,4."/%O("QPX#P'BU,7-:MX9:K[")O>5@PT+RKDP/\=;J_!Z,J
MU[.BNDB*KDW:]72:MVW=M/2$K,5;M/@6?CPZMXT9$5T]K<LRGW;%95YNDO =
MW&]:^QI']V+OP6'[YX_G;\[/WN*I2F$.)[_"-"1=O;^'LP G=]G*!%4SVBXP
MT7F7P+'M%K M$MJ8;CO2I;"L[3JK\"[P=Y+/YSRS29-?%"V<>MIU;0>;B7[C
MMY,Y!6<PBH.LW=^;Y?.B@GTQR<OZ"G8/7B?;*IGE;=' Q?"@HFW7.3V^S<L2
M/Z$MYA;/;#OS69M?PMXO8<WQVZKNDE_KHNK*36KOK?MT?V_>U$L[ KR#&S*<
M SLX.(3+&O;O?(WWA]M-FV("+S*8M'NSE5Z^^B?<#??3\U=OSE64O-S?>_KJ
MY=L7S\[?G+U[\0HWVDN=J^6Z6V<E;*[+O((=T^(VZS):[\$T\0K"QDMJ^&F3
M7-3UC#ZZS,IU-BES_'$+DD0V&-Z_R:=YL>)MF<WRW];9=+._!P^_6A2P$U!B
MH4R9P&I-WU?U59G/+O)9N,F&^R;)<$RXP',0&_55^X\_RPHZ9?SD^[,W[UX\
M_>E<%NF(M.J3-_#09^?/7[P$[0MK]F=YK:T;\^3HY.__]S>G#[]]?*/_ <WP
M#$43"T54#4?[>\]A=X(X08FQJEN5">$NQKW%^P8U%TO810;BD0Y$GE7P<4S(
MOD4I6E<\D?!2?YI-%U^=$UP;8]%,?UL7#<[(:]"T=65T[?Y>N\!)[4\2'$ 1
MJ2"C0?LO:#)QOH*I>G3TZ Y+6/Y?W*D?L*7MM.&+WMQD/3PZ.?CU+ALWGSI?
M\WE1%F!Y!%.&<X1FSD8V'TQ<!B=U!@; %(R!!$XUW%'_ZA9-O;Y8@*6:XS>D
MY N4J\M\5F1-@4-'/=;494L_;?7/$NV8C7S&9@]8V$MXH%RPOW=5P)'/=!Q9
MZ]>J)76U;EDWBDT&YM0:/N![O5F7N>SYXR]'S:I[O+C@#'1U$UG:\Z923^CO
MV7+U./E7O:XNTH1FNX8] 9Y#4M93]IXZ<)5@ G_.FO<@A=_"3GB]*$JP'\K5
MHLC@K[/DY-N3XX?W=R:?U%DS(T/I&>WZ.G!^$IY4W%H3O!"UW$ROZYG!]WB.
MUBT8JBVX*,^RS7!VR#_)-F*L@D !28L.+7P&PX'#F9$@X*_ICTJL4A0)>3,M
MP#">9-7[%H_[.YS1HMO@[.+;_:MNWI,\R-;=HFZ*?Z-?#K=K<E2C+&; )4=A
MW^1+L*B3:0D&R>QQ B-?-?4EV,DS''2*'RSJ*W2$^&^TL*<ER#$X%61)I\,1
ML8Y!?VF2@VL#E@WIE<D'CR>9@=<&'\JT@E.XP?.WJ)>Y3&?JOEOD)<A!6) '
MJS*;#KZOZNH!+ <&$F"<^7)5UIM<K^*M0T/"A>%9;XLE'&M8@P8D)8EJ</BZ
MIIBRGUNS],2!8AP"9AY_NEIL6I@8F(DFJV"U2&K0]3!NO)Y/ GH@\HL+\&Z:
M"HT_^)7,3P=N2%O#CTDST^]R#$ T=55,P66L9O AQ<=PG)L67.4V.? !#URD
M*WB0NZ@]Q,?MO'4N\HH=7YB255[1_4"UX#)-8?O#]..$5*Q]8'?>WV/\%)87
M9C2B-'3Q<;Y%J&DD@ ,-69GK%T;%VO!'8%N='IW<^VE$81@85T97O&LRVKO/
MK+!#.2)S^ ZW<L9'YUD]7>.)$==H@A'+_'>89%+0,/F@C LX5BQ9\-?9:E7"
MN<0XP"IK<"4HA(4!0XX<X)-,%&N%L0%\&5RG@^*0IQ/OY -^?V]:>H=Z G,A
MIQSC01D]LB!YL9+@UMOU!"WL%0W_; GV!8<=#@IS[_T]48MRY[9_:WFMWIY*
M\1Q3# )CY*F9DQ9^VG+<% 1"!K^=I<EDW>$/JCH!J0[#*&%)1 61\UDT+<:4
M3[Y[^\OK[]ONNR_POX?!^A@'%44:W( ")?7\#N_@O_E\P/_UX$'RO,C+V3^2
MU]E%_ABN_VV=5],<;IL\>""YL>^>O?@O?2;?Z4%7K^"2TU6G]WXPJ3L0A_](
MOL+/)J0JW&=/0 ^]3T[@X6U=%C,8P.OP?C0R^Z+??0'/C#Q^TN39^P>3'.0P
MC'%%8[9#^BHR(ASFAS[23,P7.#,\&3>XFG=,*H$^+-JV[R)[F?1+5:!$>8O!
MZ" +@T?W_'>0 ]4%V;)RFSN\_6]@JNIJ?^]M5T_?QP6X^*HM7M$S\U,4NA2)
MS9/_.#XZ/CY)5FBY+,!&%?'KS"XP+EMR$TSL'/SG6C0"FAQ@'/GOEB"/4/AD
M<Q1C$XKJXBT*E7N\2K._R-HDYV!2PTRC=HR['>,Y"3%I45<5$JN06;^JU^4L
M0>.Y*SEPM*A+"2"@W*=D#L7H0(EE'3VG@Q=.>&P)#0WUE%BH[%O7H(E*L+([
M<20X:3,!CQK4+UBMJ+];_B4EVM.D7O&55UG3H!'E7*2"8AV4,,+H3%*TX3A
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M9K6B?4.W\RE/-G[PDXW-+*!6E37Y-^LJRH.H2DJ4FXY%%SK[,86-T3EFZT%
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M.^9!'LR*<JUQ%(T"^YIN8D>?3O,R]]&6*6[54J)2![I#E#2(IRV-3QKZYXP
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MGEHJSUMI%X&9"8Z,^9BYE8"=%F ,ZXYI(XS-F@+?<>1C+&W,9X^0F*Y>B2T
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M0PC<ATSB]4"+P.&/CTYW;9-;6>JJK1VBU15"!*M +F+0O2"$-6Y]YIA[:^<
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M/!-D:K-2ZLRH8VK9<1]!:;'E]D.#S!J@>E/JT2>W:?)B.<'*?ZX=P6JJ 54
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MK\0.;2"T?])@"0YXI[@.9 8FQ^]*1>6]5G[A:1%_@W?X=0U"$#*WI2^%IC?
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M>B%7@>Y:KF"C=1=V(XS=89\7F2X,JE5HGO&[V!7%_1D]*4,.^VUR05H-VNE
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M#IP4=0VWZ?Y>I)LEOM G=;(,P"W4GE+&YOI3AITDL1#W::16:ZP><R!>-'C
M-]Z&FHD?:.OI(YT:<SB2%6)B&P/*Y-Z]NFLDW[9QP5(_B]5V[A"<%%AU8,-\
M8F1Q#.[B (*%G" ^3TU^68 ^FS#\O+$'W,,>&6HD)H_&8ATS5Y-+RQ_N-9%I
M)%@C*JEIK=#'9$PU)454?-?OD9X&VJ)DDIZ.L2HF8$88Z)AK5(S7$L:]BVK
MSK:<,(68%TVMW.[*I[/,81>=^UTDU>RNWAG'&0;OO33%1*NOQS6H;A?7K6PL
M4:6Z"&R2%/E\3N^$V9&);+&6;RI'K[ZM8/=FY[ =P=WZ<4&-\%[F&@6D46N(
MSR0=7(YB"*CP,VNJ>AD&08KPHW 04LGZW(B&J(1Q1T"V."R34YU#1CBA\DO
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M(<3:DMVJ6,@VR@14$OR$)V[Y!RB7F@.Y. !:*#FHJ1;QC*294'.&W#[ VK*
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M38)6%H+GBZ<:AV[W8A<#L#<W-[L C80F[YJ)AK6XS70EKAMLU #G$R1#,'I
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M]M)TZX!8)!^T B3<Z)_SXDTPCP1.+G2# +.VZ96U&M4NU?4_>X)CYNW[X]Y
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M,Z&85+=SDI5Q407/]W[\P14BXHPB;UD1[T[QRD7!#5]1>$M"JDH?ST4K61]
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M3SZA19R)#BQ7 B[[,@5-LI*OS')XE;H6/73H6;YP--7X;3_M[_?&.[V??J8
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M7&0[<TS>=I/8M?+$@#B1GS055U%Y95L8_:!N:YIQNYT:M@0/6RV+C+1K;XG
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M)PWQ/DY<,[,-938FJMX\?R]'] 9M+QV18&<^U;![.BU:YKB'5FK0@% 3B3&
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MDM]@9]L$BC<_2L6G#'*)0!K^NH4*TJ_Y7*P\URRWHV$P(&+F3E<B:"CW@)3
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M16[=(8OUK&:_ZETUDY"5UGHIKB_(0-[/-=3$J<U+$^[J631D.>0$'#P!+ID
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M'Y[ZOV_I[WYZ^.'X-R3)I^]&[T_?_']02P,$%     @ 38D<6PU*V-:V"@
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MSBY^RWA:2@T=)[#%C+[<BAW 'I&WN.8FNMG:B1E,MH$Y!#CNEV=C)<F6AX'
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M2P$"% ,4    " !-B1Q;?*-.P/T*  !_A@  %0              @ %6 P
M8V=T>"TR,#(U,#@R-U]L86(N>&UL4$L! A0#%     @ 38D<6V8.C>Q8!P
MSE<  !4              ( !A@X  &-G='@M,C R-3 X,C=?<')E+GAM;%!+
M 0(4 Q0    ( $V)'%NL0\+1NQ4  '=W   2              "  1$6  !T
M;3(U,C0U-S9D,E\X:RYH=&U02P$"% ,4    " !-B1Q;XKLA9X(L   VT
M%0              @ '\*P  =&TR-3(T-3<V9#)?97@Q+3$N:'1M4$L! A0#
M%     @ 38D<6\<B3F@&F   *0,# !8              ( !L5@  '1M,C4R
M-#4W-F0R7V5X,3 M,2YH=&U02P$"% ,4    " !-B1Q;R80?G;-$   "90$
M%0              @ 'K\   =&TR-3(T-3<V9#)?97@T+3$N:'1M4$L! A0#
M%     @ 38D<6PU*V-:V"@  (2T  !4              ( !T34! '1M,C4R
F-#4W-F0R7V5X-2TQ+FAT;5!+!08     "  ( !("  "Z0 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>tm2524576d2_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cgtx-20250827.xsd" xlink:type="simple"/>
    <context id="AsOf2025-08-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001455365</identifier>
        </entity>
        <period>
            <startDate>2025-08-27</startDate>
            <endDate>2025-08-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-08-27" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-08-27" id="Fact000004">0001455365</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-08-27" id="Fact000008">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-08-27" id="Fact000009">2025-08-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-08-27" id="Fact000010">Cognition Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-08-27" id="Fact000011">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-08-27" id="Fact000012">001-40886</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-08-27" id="Fact000013">13-4365359</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-08-27" id="Fact000014">2500 Westchester Ave.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-08-27" id="Fact000015">Purchase</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-08-27" id="Fact000016">NY</dei:EntityAddressStateOrProvince>
    <dei:CityAreaCode contextRef="AsOf2025-08-27" id="Fact000017">412</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-08-27" id="Fact000018">481-2210</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-08-27" id="Fact000019">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-08-27" id="Fact000020">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-08-27" id="Fact000021">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-08-27" id="Fact000022">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-08-27" id="Fact000023">Common Stock, $0.001  par value&#x202f;per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-08-27" id="Fact000024">CGTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-08-27" id="Fact000025">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-08-27" id="Fact000026">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2025-08-27" id="Fact000027">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
